WO2005018673A1 - Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby - Google Patents
Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby Download PDFInfo
- Publication number
- WO2005018673A1 WO2005018673A1 PCT/JP2004/012336 JP2004012336W WO2005018673A1 WO 2005018673 A1 WO2005018673 A1 WO 2005018673A1 JP 2004012336 W JP2004012336 W JP 2004012336W WO 2005018673 A1 WO2005018673 A1 WO 2005018673A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cardiac hypertrophy
- pkdl
- cardiomyocytes
- protein kinase
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Definitions
- the present invention offers a new understanding that relates to the mechanisms inducing cardiac hypertrophy, and more particularly to the signal transmission route leading to cardiac hypertrophy.
- the present invention also relates to a composition to suppress the onset of cardiac hypertrophy based on the findings in question (composition to suppress cardiac hypertrophy) .
- the present invention further relates to a composition that, based on the above action, is used to prevent or remedy the onset of impaired cardiac function such as heart failure specifically caused by cardiac hypertrophy (composition to prevent or remedy heart disease caused by cardiac hypertrophy) .
- the present invention relates to a method to suppress cardiac hypertrophy in patients based on the new understanding related to the mechanism generating cardiac hypertrophy, and relates to a method to prevent or remedy heart disease caused by cardiac hypertrophy (specifically, impaired cardiac function such as heart failure) .
- the present invention also relates to a method to screen the active ingredients of the aforementioned composition (composition to suppress cardiac hypertrophy, or composition to prevent or remedy heart disease caused by cardiac hypertrophy) .
- the present invention further relates to a disease animal model to show the disease of cardiac hypertrophy. BACKGROUND ART
- the heart is an organ that is differentiated extremely early during genesis of the individual, and begins to beat autonomously immediately after differentiation.
- Cardiomyocytes maintain a capacity to divide even after differentiation, and continue to actively increase by division in the fetal period, but that capacity for growth suddenly drops after birth. As a consequence, it appears that post-natal cardiomyocytes have no capacity for regeneration, and that subsequent growth of the heart occurs only by physiological enlargement, specifically, by increasing the size of the individual cardiomyocytes . Enlargement of the heart (cardiac hypertrophy) is caused either by an increase of the width of the myoblast fibers (this produces thickening of the heart walls, specifically, "concentric hypertrophy” ) , or by an increase of the length of the myoblast fibers (this produces expansion of the chambers, specifically, "eccentric hypertrophy”).
- contrasting hypertrophic forms are derived respectively by parallel assembly and serial assembly of the sarcomeres.
- Cardiac hypertrophy is induced by response to postnatal physiological adaptation or by movement, but this is a normal physiological phenomenon because a balance is simultaneously produced between the aforementioned concentric hypertrophy and eccentric hypertrophy, the pump transport capacity of the heart is increased corresponding to the increase in the amount of demand. Meanwhile, a pathologically generated load on the heart may also induce cardiac hypertrophy.
- cardiac hypertrophy occurs, specifically, the heart changes shape, mainly by hypertrophic growth of cardiomyocytes, in order to maintain cardiac output.
- this kind of cardiac hypertrophy appears to be a compensatory phenomenon for impairment of cardiomyocytes and mechanical load, but if the excess load on the heart is applied continually and notable hypertrophy occurs, the systolic and diastolic functions of the heart breakdown, chronic heart failure appears based on decreased cardiac output, and the heart becomes susceptible to ischemic heart disease and prone to fatal arrhythmia.
- this type of pathological load on the heart one or the other of concentric hypertrophy or eccentric hypertrophy may predominate, and even if not leading to heart failure, hypertrophic myocardosis or eccentric myocardosis may occur.
- Cardiac hypertrophy has lately become recognized as one of the independent risk factors leading to coronary disease such as heart failure, and the Framingham Heart Study, which was a large-scale follow-up study conducted in the US, demonstrated that when cardiac hypertrophy is present, there is a 2.5 to 3 fold increase in the percentage of onset of heart failure, ischemic heart diseases such as angina pectoris and myocardial infarction, and cardiovascular diseases such as arrhythmia (Chikara Yamazaki, Yoshio Yazaki, "Cardiac Failure”:, pages 37-45, Shigetake Shinoyama ed. , Iyaku Janarusha (Medicine & Drug Journal Co.,Ltd.), 1997).
- cardiac hypertrophy signaling pathways relating to the mechanisms producing cardiac hypertrophy have been indicated. And, it is reported that the onset or development of cardiac hypertrophy is based on the activation of the signaling pathways by stimulus factors, subsequent protein synthesis, assembly and organization of sarcomeres, and regulation of gene expression (Chien, K.R., Cell, 98, p555-558, 1999; Nicol, R.L., et al. , Ann. Rev. Gen. Gen., 1, p. 179-223, 2000; Sugden, P.H. et al., J. Mol. Med., 76, p. 725-746, 1998).
- protein kinase for example, the mitogen- activated protein kinase (MAPK) family such as ERK, JNK, and p38MAPK
- fluid factors for example, vascular action substances such as angiotensin II, and endothelin-1, neural factors such as norepinephrine, cytokines such as cardiotrophin 1, and leukemia inhibitory factor (LIF), and growth factors such as cytokine, insulin, and IGF-1).
- vascular action substances such as angiotensin II, and endothelin-1
- neural factors such as norepinephrine
- cytokines such as cardiotrophin 1
- growth factors such as cytokine, insulin, and IGF-1).
- the aforementioned protein kinase is activated by fluid factors, and it appears that through the activation response transcription factors such as c-fos, c-myc, c-jun are activated, thus inducing proteins related to cardiac hypertrophy.
- a mechanical load such as extension of the cardiomyocytes
- the aforementioned protein kinase is activated by fluid factors, and it appears that through the activation response transcription factors such as c-fos, c-myc, c-jun are activated, thus inducing proteins related to cardiac hypertrophy.
- angiotensin II endothelin-1 and norepinephrine elevate intercellular calcium levels
- cardiac hypertrophy is induced in mice that express constitutively active calcineurin (Olson et al.. Cell, 93, p. 215-223, 1998)
- recent attention has focused on the role of calcium in the formation of cardiac hypertrophy.
- Ca 2+ /calmodulin-dependent protein kinase II (CaM kinase II) activity was elevated approximately 2 times (Mol Endocrinol 14, p. 1125-1136, 2000), and because cardiac hypertrophy was observed in mice with heart specific expression of constitutively active CaM kinase IV (J Clin Invest 105, p. 1395-1406, 2000), it appears that CaM kinase II and IV are also factors that stimulate formation of cardiac hypertrophy.
- ACE angiotensin conversion enzyme
- protein kinase DI (called PKD1 hereinafter) is a protein comprising approximately llOKDa (910-920 amino acid residues) that has a control region in the amino terminal region, and a catalytic region that codes protein kinase specific to serine-threonine in the carboxy terminal region. Further, in the aforementioned control region, there are a transmembrane region (TM), two CR (Cys-rich) domains comprising a continuous zinc finger (Cys-rich, Zn finger-like), and a PH (Pleckstrin Homology) domain (refer to Fig. 1) .
- TM transmembrane region
- CR Cys-rich domains comprising a continuous zinc finger
- PH Pleckstrin Homology domain
- the molecule of human-derived PKD1 is folded by the interaction between the CR domain of the control region and the catalytic region, and in this state is thought to be inactive (inactive PKD1).
- active PKD1 phosphoinositide-dependent kinase 1: PDKl
- the CR domains have a high affinity to Ca 2+ , diacylglycerol (DG) or phorbol ester (for example, TPA, etc.), and when these components are bound to the CR domains, the catalytic region separates from the CR domains, becomes all the more active, and then the molecule as a whole is fully activated by the catalytic region (Ser-916) of the C terminal undergoing self-phosphorylation (fully active PKDl) (Van Lint, J., et al., J. Biol. Chem. 3, p. 1455- 1461, 1995; Switzerlandaza, J.L., et al., EMBO J. 15, p.
- DG diacylglycerol
- TPA phorbol ester
- PKDl was identified as one (PKC ⁇ ) of the protein kinase C (called PKC hereinafter) family from the structural characteristics thereof, but for reasons such as the amino acid sequence of the catalytic region differs from that of the PKC family (the amino acid sequence of this region is highly conserved among the PKC family) , it now appears that PKDl belongs to an independent protein kinase family that differs from PKC.
- PKC ⁇ protein kinase C
- PKC ⁇ , PKC ⁇ , PKC ⁇ l activate PKDl based on phosphorylation of the active loop residue (Ser-744) of human-derived PKDl and the residue adjacent thereto (Ser-748)
- Ser-744 active loop residue of human-derived PKDl
- Ser-748 residue adjacent thereto
- PKDl is expressed and is present in many tissues in the human body such as the brain, lungs, heart and skeletal muscles, and especially in the heart. It is known that some PKDl is localized in the Golgi apparatus (Iglesias, T., et al., FEBS Lett. 454, p. 53-56, 1999; Jamora, C, et al.. Cell. 98, p. 59-68, 1999; Liljedahl, M. , et al.. Cell. 104, p. 409-420, 2001), and plays an important role in Golgi function (Van Lint, J., et al.. Trends in Cell Biol. 12, p. 193-200, 2002).
- PKC protein kinase C
- Fig. 1 is a conceptual diagram indicating the domain structure of protein kinase DI, and the structural changes of the inactive and active forms .
- Fig. 2 indicates the Western blot results when comparing TPA (12-0-tetradecanolyphorbol 13-acetate)- treated and TPA-untreated (None) neonate rat cardiomyocytes (called NRC hereinafter) regarding the intracellular distributions (cytoplasm, membrane) of fully active PKDl (phosphorylated PKDl) and inactive PKDl (non- phosphorylated PKDl).
- TPA is one kind of phorbol ester known to activate PKC and PKD.
- Fig. A TPA-treated NRC
- Fig. 3B untreated NRC
- Fig. 3A TPA-treated NRC
- NE norepinephrin
- the NE includes proplanol ( ⁇ -blocker) to suppress the action of ⁇ - adrenaline receptors in NRC. The development of sarcomere structures (cardiac hypertrophy state) by NE treatment was revealed.
- NE treatment only causes the fully active PKDl (phosphorylated PKDl) to move to the sarcomere Z-disc, and to become localized there.
- Fig. 5 is a figure indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin, fully active PKDl (phosphorylated PKDl), and inactive PKDl (non- phosphorylated PKDl) in NRC treated with angiotensin II (called Angll below) (100 nM) which induces cardiac hypertrophy (Experiment 3). The formation of sarcomere structures (cardiac hypertrophy state) by Angll treatment was revealed.
- Angll treatment causes only the fully active PKDl (phosphorylated PKDl) to move to the sarcomere Z-disc, and to become localized there.
- Fig. 6 is a figure indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin, fully active PKDl (phosphorylated PKDl), and inactive PKDl (non- phosphorylated PKDl) in NRC treated with LIF (leukemia inhibitory factor) , which induces cardiac hypertrophy (Experiment 3). The formation of sarcomere structures (cardiac hypertrophy state) by LIF treatment was revealed.
- Fig. 7A indicates the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -a ⁇ tinin and fully active PKDl
- NE (+ propranolol) -induced cardiac hypertrophy state, activation of PKDl, and translocation to the sarcomere Z-disc are dependent on PKC activation.
- Fig. 7B indicates the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin and fully active PKDl (phosphorylated PKDl) after treating NRC with GF109203X in the same way and then treating with the cardiac hypertrophy inducer: LIF (Experiment 3).
- Fig. 8 is a figure indicating the results of investigating the phosphorylation activity of PKDl present in NRC or NRC treated with various types of drugs (Experiment 4). The abscissa indicates the type of NRC treated (or not treated) with the various types of drugs.
- Indicated from the left are: (1) untreated cells, (2) TPA- treated cells, (3) Norepinephrine (+ propranolol) (NE) treated cells, (4) LIF-treated cells, (5) GF109203X- treated cells, (6) GF109203X + TPA-treated cells, (7) GF109203X + NE (+ propranolol) treated cells, and (8) GF109203X + LIF-treated cells.
- the ordinate indicates the phosphorylation activity (%) of PKDl present in the various cells.
- the phosphorylation activity (%) is the relative % when taking the phosphorylation activity of PKDl present in untreated cells as 100%.
- FIG. 9 is a figure indicating the results of investigating the changes in phosphorylation activity of intrinsic PKDl when conducting NE (+ propranolol) treatment of normal NRC, and NRC with inhibited activity caused by transient expression of various types of kinase dead PKCs (PKC ⁇ , PKC ⁇ l, PKC ⁇ , PKC ⁇ , PKC ⁇ ) (Example 5).
- the abscissa indicates the types of NRC.
- Fig. 10 is a figure indicating the results of an immunoprecipitation assay using the immunoprecipitation method and the Western blotting method to investigate the form of PKD ⁇ and PKDl present in NE (+ propranolol) treated NRC (Experiment 6).
- Fig. 11A is a figure indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin and GFP (specifically, GFP-PKD1 CA, or GFP) in NRC with transient expression by introducing GFP (green fluorescent protein) fused with constitutively active PKDl (GFP-PKD1 CA) (lower panels), and GFP (upper panels) (Experiment 7 (1)). It is evident that only the NRC with transient expression of GFP-PKD1 CA (specifically, NRC having fully active PKDl (phosphorylated PKDl)) formed sarcomere structures
- Fig. 11B is a figure indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin and constitutively active PKC ⁇ (specifically, PKC ⁇ -CA) in NRC with transient expression by introducing PKC ⁇ -CA. Immunofluorescence was also observed for ⁇ -actinin and PKC ⁇ .
- Fig. 12 is a figure indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin in NRC with transient expression by introducing constitutively active
- panels D and E are figures indicating the results of staining by immunofluorescence to investigate the intracellular distribution of ⁇ -actinin in NRC with transient expression by introducing dominant negative PKC ⁇ (DN-PKC ⁇ ) treated with NE (+ propranolol) and LIF respectively (Experiment 8).
- sarcomere structures cardiac hypertrophy state
- panel A NRC-expressed CA-PKC ⁇
- B NRC- expressed CA-PKC ⁇ l
- E NRC-expressed DN-PKC ⁇ + LIF- treated
- Fig. 13 is a figure indicating the results of investigating the level of expression of atrial natriuretic factor (called ANF below) , which is a marker for cardiac hypertrophy, in various types of NRC.
- ANF atrial natriuretic factor
- Fig. 14 indicates the domain structure of mouse ENH1 (mENHl) (enigma homologue 1), and the domain structures of mouse ENH2 (mENH2) (enigma homologue 2) and mouse ENH3 (mENH3) (enigma homologue 3), which are splice mutants having the LIM domain of the mENHl deleted. All of the ENH molecules have PDZ domain at the N-terminal, and the mEHNl has three LIM domains at the C-terminal.
- Fig. 15 is a figure indicating the results of Example 10.
- the figure shows the NRC observed by the fluorescent antibody method using anti-FLAG antibody or anti-ANF antibody, the NRC is caused transient expression of ENH1 or ENH2, to which a FLAG epitope tag was added to the N terminal in advance, and treated with 20 nM TPA which is capable of inducing cardiac hypertrophy.
- the results of suppressing expression of ANF, which is a cardiac hypertrophy marker demonstrated that the action of TPA to induce cardiac hypertrophy was suppressed only in the NRC into which ENH2 was introduced.
- FIG. 16 is a conceptual diagram indicating a cardiac hypertrophy signal control model mediated through seven transmembrane-spanning heterotrimeric G protein-coupled receptor (called GPCR below) in cardiomyocytes.
- GPCR G protein-coupled receptor
- the present inventors studied the role of protein kinase DI (PKDl), as well as the interaction between PKDl and protein kinase C ⁇ (PKC ⁇ ) in cardiac hypertrophy signal transduction in cardiomyocytes.
- PKDl is notably expressed in cardiomyocytes, is fully activated (phosphorylated) by stimulus mediated through seven transmembrane-spanning heterotrimeric G protein-coupled receptor (GPCR) such as angiotensin II (Angll) and norepinephrine (NE), and moves into and is localized in sarcomere -discs;
- GPCR G protein-coupled receptor
- the full activation (phosphorylation) of PKDl is dependent on PKC ⁇ activation, and PKDl interacts with PKC ⁇ within cardiomyocytes and is directly activated by PKC ⁇ ;
- the cardiomyocytes indicate the same cardiac hypertrophy conditions as when treated by cardiac hypertrophy inducing agents, but after forcing the expression of inactive type PKDl (non-phosphorylated PKDl),
- PKDl as a signal factor in the signaling pathway generating cardiac hypertrophy (cardiac hypertrophy signaling pathway) , and indicate that PKDl induces cardiac hypertrophy by being directly activated by PKC ⁇ , and is a downstream factor of PKC ⁇ .
- cardiac hypertrophy signaling pathway cardiac hypertrophy signaling pathway
- PKDl inhibitor may be useful as cardiac hypertrophy suppressants and as medicinal agents to prevent or remedy heart disease
- ENH1 is a scaffold protein that recruits and links the signal factors (PKC) that participate in cardiac hypertrophy signaling to the cardiomyocyte sarcomere Z-discs (Nakagawa N, et al., Biochem. Biophys. Res. Commun., 272(2), p. 505-512, 2000), but the present inventors discovered that spliced mutant ENH2 that lacks the LIM domain of ENH1 is an endogenous antagonist that suppresses cardiac hypertrophy signaling through the aforementioned ENH1. This result suggests that clinical applications as cardiac hypertrophy suppressants and as agents to prevent or remedy heart disease are possible, by suppressing and controlling the cardiac hypertrophy signaling in which ENH1 participate by forcing the expression of ENH2 in cardiomyocytes.
- PLC signal factors
- the present invention was completed based on the related knowledge, and first of all provides a pharmaceutical composition effective in suppressing cardiac hypertrophy related to the onset and development of heart diseases such as chronic cardiac failure.
- the present invention provides a cardiac hypertrophy suppressant (pharmaceutical composition to suppress cardiac hypertrophy) that has as an active ingredient a substance that suppresses the functional expression in cardiomyocytes of PKDl which is related to the cardiac hypertrophy signaling.
- the present invention provides a pharmaceutical composition that can suppress the onset and development of various types of heart disease caused by cardiac hypertrophy by using a substance that suppresses the related functional expression of PKDl in order to block or suppress the cardiac hypertrophy signaling.
- the present invention further provides a method to suppress cardiac hypertrophy and to prevent onset of cardiac hypertrophy, as well as a method to prevent or remedy the onset and development of various kinds of heart disease such as chronic cardiac failure that are caused by the aforementioned cardiac hypertrophy.
- the present invention provides a method, based on the newly discovered mechanisms of generating cardiac hypertrophy, that screens and selects hypertrophy suppressants and the components effective to remedy or prevent cardiac diseases the onset and development of which are caused by cardiac hypertrophy; and provides pharmaceutical compositions having the related components as the active ingredients (pharmaceutical compositions to suppress cardiac hypertrophy, pharmaceutical compositions to prevent or remedy cardiac diseases caused by cardiac hypertrophy) .
- the present invention provides transgenic non-human animals, specifically, non-human animals that are disease models of cardiac hypertrophy in which cardiac hypertrophy is induced and promoted by transient expression of PKDl in cardiomyocytes .
- the present invention contains the following forms.
- I Pharmaceutical composition for suppressing cardiac hypertrophy
- a pharmaceutical composition for suppressing cardiac hypertrophy which comprises a substance that suppresses functional expression of PKDl in cardiomyocytes an active ingredient.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to ( 1 ) wherein the active ingredient is a substance that has an action to suppress PKDl activity in cardiomyocytes.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to ( 1) or ( 2 ) wherein the active ingredient is nucleic acid having a base sequence that codes dominant negative PKDl which has been controlled to be able to express in cardiomyocytes .
- the pharmaceutical composition for suppressing cardiac hypertrophy according to (4 ) wherein the nucleic acid is included in an expression vector.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to ( 5) wherein the expression vector is included within a virus particle or within a hollow nanoparticle .
- the pharmaceutical composition for suppressing cardiac hypertrophy according to (5) wherein the expression vector is comprised of liposomes .
- the pharmaceutical composition for suppressing cardiac hypertrophy according to (9) wherein the active ingredient is an antisense molecule, ribozyme or RNAi effector of PKDl.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to ( 1) or (2 ) wherein the active ingredient is an antibody to PKDl or to a fragment thereof that may be phosphorylated.
- a pharmaceutical composition for suppressing cardiac hypertrophy which comprises nucleic acid having a base sequence that codes ENH2 an active ingredient.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to (13), wherein the expression vector is included within a virus particle or within a hollow nanoparticle.
- the pharmaceutical composition for suppressing cardiac hypertrophy according to (13), wherein the expression vector is comprised of liposomes.
- Method to suppress cardiac hypertrophy or to prevent the onset of cardiac hypertrophy (1) A method to suppress cardiac hypertrophy or prevent onset of cardiac hypertrophy in a patient with cardiac hypertrophy or the preconditions thereof, which comprises administering the effective amount of a substance that suppresses functional expression of PKDl in cardiomyocytes to the patient. ( 2 ) The method according to ( 1) , wherein the substance is a substance that has an action to suppress PKDl activity in cardiomyocytes. (3) The method according to (1) or (2), wherein the substance is a substance that has an action to suppress phosphorylation of at least one of Ser-744, Ser-748, or Ser-916 of PKDl derived from humans.
- the expression vector is a plasmid or a virus vector.
- the expression vector is included within a virus particle or within a hollow nanoparticle.
- the expression vector is comprised of liposomes.
- cardiac hypertrophy is caused by cardiac hypertrophy signal transduction through GPCR or EGF receptor.
- composition to prevent or remedy heart disease caused by cardiac hypertrophy (1) A pharmaceutical composition to prevent or remedy onset of heart disease caused by cardiac hypertrophy, which comprises a substance that suppresses functional expression of PKDl in cardiomyocytes as an active ingredient. ( 2) The pharmaceutical composition according to ( 1) , wherein the active ingredient is a substance that has an action to suppress PKDl activity in cardiomyocytes. (3) The pharmaceutical composition according to (1) or (2), wherein the active ingredient is a substance that has an action to suppress phosphorylation of at least one of Ser-744, Ser-748, or Ser-916 of PKDl derived from humans .
- the pharmaceutical composition according to (5), wherein the expression vector is included within a virus particle or within a hollow nanoparticle.
- the pharmaceutical composition according to (1) or (2), wherein the active ingredient is a substance that inhibits expression of PKDl genes in cardiomyocytes.
- the pharmaceutical composition according to (9), wherein the active ingredient is an antisense molecule, ribozyme or RNAi effector of PKDl .
- the pharmaceutical composition according to (1) or ( 2) , wherein the active ingredient is an antibody to PKDl or to a fragment thereof that may be phosphorylated.
- a pharmaceutical composition to prevent or remedy the onset of heart disease caused by cardiac hypertrophy which comprises nucleic acid having a base sequence that codes ENH2 as an active ingredient.
- the pharmaceutical composition according to (12), wherein the nucleic acid is included in an expression vector.
- the pharmaceutical composition according to (13), wherein the expression vector is a plasmid or a virus vector.
- the pharmaceutical composition according to (13), wherein the expression vector is included within a virus particle or within a hollow nanoparticle.
- the aforementioned expression vector is comprised of liposomes.
- the pharmaceutical composition according to any of (1) through (17), wherein the diseases caused by cardiac hypertrophy are heart failure, ischemic heart disease or arrhythmia.
- Method to prevent or remedy heart disease caused by cardiac hypertrophy (1) A method to prevent or remedy onset of diseases caused by cardiac hypertrophy in a patient with cardiac hypertrophy or the preconditions thereof, which comprises administering to the patient the effective amount of a substance that suppresses functional expression of PKDl in cardiomyocytes . ( 2) The method according to ( 1) , wherein the substance is a substance that has an action to suppress PKDl activity in cardiomyocytes . (3) The method according to (1) or (2), wherein the substance is a substance that has an action to suppress phosphorylation of at least one of Ser-744, Ser-748, or Ser-916 of PKDl derived from humans.
- the method according to (14), wherein the nucleic acid is included in an expression vector.
- the expression vector is a plasmid or a virus vector.
- the expression vector is included within a virus particle or within a hollow nanoparticle.
- the expression vector is comprised of liposomes.
- cardiac hypertrophy is caused by cardiac hypertrophy signal transduction through GPCR or EGF receptor.
- cardiac diseases caused by cardiac hypertrophy are heart failure, ischemic heart disease or arrhythmia.
- V. Method to block or suppress cardiac hypertrophy signal transduction (1)A method to block hypertrophy signal transduction, which comprises administering the effective amount of a substance that inhibits functional expression of PKDl to cardiomyocytes . (2) The method according to (1) , wherein the substance is a substance that has an action to suppress PKDl activity in cardiomyocytes. (3) The method according to (1) or (2) , wherein the substance is a substance that has an action to suppress phosphorylation of at least one of Ser-744, Ser-748, or Ser-916 of PKDl derived from humans.
- the method according to (1) or (2), wherein the substance is a substance that inhibits expression of PKDl genes in cardiomyocytes .
- the method according to (9), wherein the substance is an antisense molecule, ribozyme or RNAi effector of PKDl.
- the method according to (1) or (2), wherein the substance is an antibody to PKDl or to a fragment thereof that may be phosphorylated.
- a method to block cardiac hypertrophy signal transduction which comprises administering an effective amount of nucleic acid having a base sequence that codes ENH2 to cardiomyocytes .
- the method according to (12), wherein the nucleic acid is included in an expression vector.
- the method according to (13), wherein the expression vector is a plasmid or a virus vector.
- the expression vector is included within a virus particle or within a hollow nanoparticle.
- the expression vector is comprised of liposomes.
- cardiac hypertrophy is caused by hypertrophy signal transduction through GPCR or EGF receptor.
- the transgenic non-human animal according to (1) wherein the constitutively active PKDl is at least one selected from human derived PKDl with the PH domain deleted, human derived PKDl with the serines of position 744 and position 748 of the amino acid sequence substituted with glutamic acids, and mouse derived PKDl with the serines of position 744 and position 748 of the amino acid sequence substituted with glutamic acids.
- the transgenic non-human animal according to (1) or (2) which is an animal model of cardiac hypertrophy.
- the dominant negative protein kinase DI is at least one selected from human derived PKDl with the lysine of position 612 of the amino acid sequence substituted with tryptophan, human derived PKDl with the lysine of position 618 of the amino acid sequence substituted with asparagine, human derived PKDl with the aspartic acid of position 733 of the amino acid sequence substituted with alanine, human derived PKDl with the serines of position 738 and position 742 of the amino acid sequence substituted with alanines, mouse derived PKDl with the lysine of position 618 of the amino acid sequence substituted with methionine, and mouse derived PKDl with the serines of position 744 and position 748 of the amino acid sequence substituted with alanines .
- a method for screening a cardiac hypertrophy suppressant comprising the following steps: (a) bringing a test substance into contact with cells that can express PKDl; (b) measuring the levels of expression of PKDl in the aforementioned cells, and comparing with the level of PKDl expression in contrast cells that were not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as a cardiac hypertrophy suppressant the test substance which, when brought into contact with cells, lowered the level of expression of PKDl as compared to the contrast cells .
- a method for screening a cardiac hypertrophy suppressant comprising the following steps : (a) bringing a PKDl activator and a test substance into contact with cells that can express PKDl; (b) measuring the activity of PKDl in the aforementioned cells, and comparing with the activity corresponding to the above in contrast to cells that were not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as a cardiac hypertrophy suppressant the test substance which, when administered to cells, lowered the activity of PKDl as compared to the contrast cells.
- a method for screening a cardiac hypertrophy suppressant comprising the following steps: (a) bringing a test substance and a cardiac hypertrophy inducer that stimulates GPCR or EGF receptor into contact with cardiomyocytes; (b) measuring the PKDl activity, localization of phosphorylated PKDl in sarcomere Z-discs, or the intermolecular distance of PKC ⁇ and PKDl in the aforementioned cardiomyocytes, and comparing with the corresponding activity, localization or intermolecular distance in contrast to cardiomyocytes that were brought into contact with hypercardia inducer only; and (c) based on the comparative results of (b) above, selecting as cardiac hypertrophy suppressants the test substance administered to the cardiomyocytes that lowered the activity of PKDl, or lowered the localization of phosphorylated PKDl in sarcomere Z-discs, or increased the intermolecular distance of PKC ⁇ and PKDl compared to the contrast cardiomyocytes .
- a method for screening a cardiac hypertrophy suppressant comprising the following steps : (a) bringing a test substance into contact with cardiomyocytes that can express constitutively active PKC ⁇ or constitutively active PKDl; (b) measuring the PKDl activity, localization of phosphorylated PKDl in sarcomere Z-discs, or the intermolecular distance of PKC ⁇ and PKDl in the aforementioned cardiomyocytes, and comparing with the activity, localization or intermolecular distance corresponding to the above in contrast cardiomyocytes that were not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as a cardiac hypertrophy suppressant the test substance administered to the cardiomyocytes that lowered the activity of PKDl, or lowered the localization of phosphorylated PKDl in sarcomere Z-discs, or increased the intermolecular distance of PKC ⁇ and PKDl compared to the contrast cardio
- a method for screening cardiac hypertrophy suppressants comprising the following steps: (a) administering a test substance to transgenic non-human animals according to any of IV (1) to (3); (b) measuring the degree of cardiac hypertrophy of the aforementioned non-human animals, and comparing with the extent of cardiac hypertrophy of contrast transgenic non-human animals that were not administered the test substances; and (c) based on the comparative results of (b) selecting as cardiac hypertrophy suppressants the test substances that reduce or suppress cardiac hypertrophy. (9) The method for screening according to any of (1) through (8), which is a method for acquiring active ingredients for pharmaceutical compositions to prevent or remedy heart disease caused by cardiac hypertrophy. (10) The method for screening according to (9), wherein the heart disease caused by cardiac hypertrophy is heart failure, ischemic heart disease or arrhythmia.
- (VIII) Use (1) Use of a substance that suppresses functional expression of PKDl in cardiomyocytes, or of nucleic acid having a base sequence to code ENH2, for manufacturing pharmaceutical compositions to suppress cardiac hypertrophy. (2) Use according to ( 1 ) , wherein the substance that suppresses functional expression of PKDl in cardiomyocytes is a substance that suppresses the activity of PKDl in cardiomyocytes or a substance that prevents expression of PKDl genes in cardiomyocytes. (3) Use of a substance that suppresses functional expression of PKDl in cardiomyocytes, or of nucleic acid having a base sequence to code ENH2, for manufacturing pharmaceutical compositions to prevent or remedy onset of heart diseases caused by cardiac hypertrophy.
- the substance that suppresses functional expression of PKDl in cardiomyocytes is a substance that suppresses the activity of PKDl in cardiomyocytes or a substance that prevents expression of PKDl genes in cardiomyocytes.
- composition to suppress cardiac hypertrophy Cardiac hypertrophy is caused by increased load based on exercise, and disease factors such as increased pressure load based on hypertension, increased volume load based on valvular disorders, and increased load based on diseases of unknown cause.
- the cardiac hypertrophy of the present invention means the latter, specifically, myocardial disease conditions, such as compensatory hypertrophy of the heart and hypertrophic myocardial disease, in which the volume of the heart has increased beyond the range of physiological hypertrophy, based on various stresses such as hemodynamic overload and liquid factors by the disease condition.
- hypertrophy of various parts of the heart such as left ventricular hypertrophy, right ventricular hypertrophy, bilateral ventricular hypertrophy, and atrial hypertrophy may arise depending on the part where cardiac load is applied, but these types of hypertrophy are not particularly distinguished in the present invention.
- the overload applied to the heart is pressure load, there is a tendency for the wall thickness to increase notably and for the inner chamber to become deformed or narrowed (concentric hypertrophy); and if the overload applied to the heart is volume load, there is a tendency for the inner chamber to expand without that much increase in wall thickness (eccentric hypertrophy). In the present invention, however, these types are not particularly distinguished.
- the present invention may be suitably used on the former, concentric hypertrophy, which indicates a shape with increased wall thickness.
- the cardiac hypertrophy targeted by the present invention is induced via signal transduction generated through activation of G-proteins mediated by 7- pass membrane G protein-coupled receptors (GPCR), or through activation of receptor tyrosine kinase mediated by epidermal growth factor receptors (EGF receptors).
- GPCR 7- pass membrane G protein-coupled receptors
- EGF receptors epidermal growth factor receptors
- compositions for suppressing cardiac hypertrophy of the present invention comprise as active ingredients substances that suppress the functional expression of PKDl in cardiomyocytes.
- suppression includes both 100% suppression (inhibition) of the functional expression of PKDl, and reduction of the original function of PKDl without 100% inhibition.
- the substances may be ones that result in suppression of the functional expression of PKDl in cardiomyocytes, and the following may be cited as examples: substances that suppress the expression or production of PKDl in cardiomyocytes, substances that block or suppress PKDl activation signals in cardiomyocytes, and substances that suppress the activation (including phosphorylation) of PKDl in cardiomyocytes.
- substances that suppress the transcription, RNA processing, transfer, translation and/or stability of PKDl genes during the expression or production of PKDl in cardiomyocytes may be cited as examples of substances that suppress the expression or production of PKDl in cardiomyocytes.
- antisense molecules, ribozymes and RNAi effectors that can hybridize with the base sequence of genes that code PKDl and can suppress the transcription, RNA processing, transfer, translation and/or stability thereof may be cited as examples of such substances .
- the antisense molecules used in the present invention are designed to bond to the promoter or other control region, exon, intron, or exon-intron boundary of PKDl gene.
- the antisense molecule of the present invention preferably has a substantially complementary base sequence to the aforementioned region.
- Ribozymes are RNA-protein complexes, and are substances that manifest functions to inhibit translation to proteins and to suppress functional expression of gene by site-specific bonding to the target gene (mRNA) and cutting.
- RNAi effectors are substances that hybridize to the upstream region of PKDl DNA or mRNA, and specifically suppress the expression of PKDl genes by functioning RNAi (RNA interference).
- RNAi effectors siRNA (small interfering RNA), stRNA (small temporally regulated RNA), and shRNA (short hairpin RNA) may be cited.
- RNAi technology utilizing RNAi effectors and methods thereof are described in detail in Kazushi Taiyoshi, et al, ed. "RNAi Experimental Protocol", YODOSHA CO. LTD., 2003, and the contents of the document are hereby incorporated by reference.
- nucleic acids that code for dominant negative PKDl controlled to be capable of expression in cardiomyocytes may be understood as substances that suppress expression or production of PKDl in cardiomyocytes.
- mutation in the ATP binding position of PKDl (for example, Lys-residue of position 612 in human derived PKDl, and Lys-residue of position 618 in mouse derived PKDl) predominantly suppresses the kinase function thereof.
- PKDl for example, Lys-residue of position 612 in human derived PKDl, and Lys-residue of position 618 in mouse derived PKDl
- mutation in the ATP binding position of PKDl for example, Lys-residue of position 612 in human derived PKDl, and Lys-residue of position 618 in mouse derived PKDl
- PKDl human derived PKDl with the lysine of position 618 (Lys-618) of the amino acid sequence substituted with asparagine (K618N PKDl), human derived PKDl with the lysine of position 612 (Lys-612) of the amino acid sequence substituted with tryptophan, human derived PKDl with the aspartic acid of position 733 (Asp-733) of the amino acid sequence substituted with alanine, human derived PKDl with the serines of positions 738 and 742 of the amino acid sequence substituted with alanines, mouse derived PKDl with the lysine of position 618 (Lys-618) of the amino acid sequence substituted with methionine, and mouse derived PKDl with the serines of positions 744 (Lys- 744) and 748 (Lys-748) of the amino acid sequence substituted with alanines.
- the nucleic acids coding for dominant negative PKDl is normally used in a state operably bound to the functional DNA sequence required for expression of the related nucleic acids in cardiomyocytes.
- functional DNA means the control region or regulatory element necessary in order for nucleic acids coding for dominant negative PKDl to be expressed in cardiomyocytes, and polyadenylated signals, upstream sequence domains, promoters, enhancers or terminators may be cited as examples.
- promoters include SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), simple herpes promoter, CMV promoter (for example, CMV initial promoter, Raus sarcoma virus (RSV) promoter), myosin light chain 2 promoter, ⁇ -actin promoter, troponin 1 promoter, Na + /Ca 2+ substituted promoter, dystrophin promoter, creatine kinase promoter, ⁇ 7 integrin promoter, brain natriuretic peptide promoter, ⁇ B-crystallin/small heat shock protein promoter, ⁇ -myosin heavy chain promoter, and ANF promoter.
- CMV promoter for example, CMV initial promoter, Raus sarcoma virus (RSV) promoter
- myosin light chain 2 promoter for example, CMV initial promoter, Raus sarcoma virus (RSV) promoter
- these promoters are ones that can be expressed tissue specifically in cardiomyocytes.
- "operably bound” means that the nucleic acid that codes for dominant negative PKDl is present in a state that can be expressed in cardiomyocytes irrespective of the binding position and direction with respect to the aforementioned various types of functional DNA sequences.
- the present invention provides as a substance to suppress and control the cardiac hypertrophy signal cascade in cardiomyocytes a nucleic acid having a base sequence that codes for ENH2 controlled to be capable of expression in cardiomyocytes.
- the nucleic acid in question is normally used in a state operably bound to a functional DNA sequence necessary for the expression of the nucleic acid in cardiomyocytes.
- Base sequences codig for ENH2 have already been widely known by Nakagawa N. et al. (Nakagawa N, Hoshijima M, Oyasu M, Saito N, Tanizawa K, Kuroda S., ENH containing PDZ and LIM domains, heart/skeletal muscle-specific protein, associates with cytoskeletal proteins through the PDZ domain. Biochem. Biophys. Res. Commun., 2000 Jun 7, 272 (2), p. 505-12.), the contents of the literature are hereby incorporated by reference.
- nucleic acids are preferably provided in forms suitable for administration to test subjects, preferably, to mammals including humans.
- Expression vectors for genetic therapies may be cited as the forms in question.
- the related expression vectors for genetic therapies may be prepared and prescribed by well-known methods in this field corresponding to the desired administration route. Methods to prevent release or absorption of the target nucleic acids from the expression vector until the expression vector reaches the target organ (heart, cardiomyocytes) are well known in this field, and can be applied to the present invention in the same way.
- the expression vectors may also be used in a state forming a complex with other vehicles (for example, molecules with a lipid base such as liposome, aggregate proteins, or transporter molecules).
- These expression vectors may be transmitted to the cardiomyocytes by injection in the coronary artery or coronary sinus (called intra-coronary transmission through the coronary artery, intra-coronary artery transmission, or intra-artery transmission) (For example, refer to US Patent No. 5792453 and US Patent No. 6100242. The contents of these literature are quoted and incorporated in the present invention. ) .
- Plasmid vectors and virus vectors are included in the expression vectors of the present invention.
- virus vectors the nucleic acid coding for dominant negative PKDl or the nucleic acid coding for ENH2 is used in a state operably bound with the functional DNA sequence necessary for expression in cardiomyocytes, and in a state encloded in a viral particle.
- virus vectors well known in the field may be optionally used, and examples include adenovirus, retrovirus, adeno-associated virus, vaccinia virus, herpes virus, and polyoma virus.
- adenovirus retrovirus
- adeno-associated virus vaccinia virus
- herpes virus and polyoma virus.
- hollow nanoparticles in which bio- recognition molecules that can specifically recognize heart tissue or cardiomyocytes are introduced into a substance having the ability to form particles.
- the hollow nanoparticles in question are well known in the field as transporters for introducing a desired substance into targeted cells or tissues. A detailed description of the hollow nanoparticles in question is given in, for example, Japanese Laid-open Patent No. 2001-316298, and the contents of the gazette are incorporated hereto by reference.
- substances that suppress activation of PKDl in cardiomyocytes substances that suppress release of the CR domain from the catalyst domain of PKDl, substances that suppress phosphorylation of PKDl (for example, substances that suppress phosphorylation of at least one of Ser-744, Ser- 748 or Ser-916 of human derived PKDl), substances that suppress formation of a complex of PKC ⁇ and PKDl, substances that selectively bond to the substrate-binding sites of PKDl and suppress enzyme activity, and substances that suppress sarcomere Z-discs localization of PKDl (for example, substances that suppress recruiting of PKDl to sarcomere Z-discs, or substances that suppress PKDl bonding to scaffolds, such as ENH1, on sarcomere Z-discs).
- antibodies that react with PKDl or any parts thereof may be cited as the substances that suppress activation of PKDl in cardiomyocytes .
- the antibodies may be either polyclonal antibodies or monoclonal antibodies.
- the antibodies are monoclonal antibodies.
- Methods to prepare polyclonal antibodies and monoclonal antibodies are well known in the field, and the antibodies of the present invention may be prepared accordingly (For example, refer to Harlow and Lane, Antibodies; A Laboratory manual. Cold Spring Harbor Laboratory, 1988; and US Patent No. 4,196,265. The contents of this literature is incorporated hereto by reference. ) .
- anti-PKDl antibody this means both polyclonal antibody and monoclonal antibody
- antibody to the CR domain of PKDl anti-PKDl/CR domain antibody
- antibody to PH domain of PKDl anti-PKDl/PH domain antibody
- antibody to the phosphorylation region of PKDl for example, in the case of human derived PKDl, (1) antibody to peptide fragment of PKDl comprising at least one of Ser-744, Ser-748, or Ser 916, or (2) antibody to a peptide fragment of PKDl comprising at least one of phosphorylated Ser-744, Ser-748, or Ser 916
- antibody to catalyst region of PKDl anti- inactive PKDl antibody (stabilizes inactive PKDl)
- anti-fully active PKDl antibody bonds to PKDl in the activated state, and suppresses enzyme activity by steric hindrance.
- the pharmaceutical composition for suppressing cardiac hypertrophy of the present invention may also comprises pharmaceutically acceptable carriers and additives corresponding to the form or administration route of preparation, in addition to an effective amount of the active ingredient, which is a substance that suppresses the functional expression of PKDl in cardiomyocytes, or nucleic acid that codes ENH2.
- the pharmaceutical composition may be administered by the desired mode, for example by oral administration, intravenous administration, intramuscular administration, hypodermic administration, transpulmonary administration, transnasal administration, transintestinal administration, intraperitoneal administration or administration in coronary artery or coronary sinus .
- the pharmaceutical composition was prepared into solid administration forms such as tablets, pills, bulk drug, powder, granules and capsules, etc.; liquid administration forms such as solutions, suspensions, emulsions, syrups, liposome preparations, injectable agents, intravenous agents, drip agents, and elixirs, etc.; and external dosing forms such as patches, ointments, creams and sprays.
- solid administration forms such as tablets, pills, bulk drug, powder, granules and capsules, etc.
- liquid administration forms such as solutions, suspensions, emulsions, syrups, liposome preparations, injectable agents, intravenous agents, drip agents, and elixirs, etc.
- external dosing forms such as patches, ointments, creams and sprays.
- Examples of carriers used to formulate these pharmaceutical compositions include fillers, diluents, binders, moisturizers, disintegrators, disintegration suppressants, absorption promoters, lubricants, dissolution supplements, buffers, emulsifiers, and suspending agents.
- Examples of additives, as commonly used corresponding to the form of administering the preparation include stabilizers, preservatives, buffers, extenders, chelates, pH adjusters, surfactants, colorants, fragrances , flavors , and sweeteners .
- the pharmaceutical composition for suppressing cardiac hypertrophy of the present invention may also comprises substances that block the cardiac hypertrophy signaling pathway but are not mediated through stimulus for seven transmembrane-spanning heterotrimeric G protein- coupled receptors (GPCR) or epidermal growth factors (EGF) receptors, for example, substances that block the cardiac hypertrophy signaling pathway mediated through gpl30 receptors (gpl30 receptor inhibitor) such as cytokine receptor blockers and LIF inhibitors, in addition to an active ingredient which is substances that suppress the functional expression of PKDl in cardiomyocytes or nucleic acids that codes ENH2.
- GPCR transmembrane-spanning heterotrimeric G protein- coupled receptors
- EGF epidermal growth factors
- the amount of active ingredient to be contained in the aforementioned pharmaceutical composition and the dosage thereof are not particularly limited, and may be suitably selected in a range corresponding to the desired therapeutic effect, administration manner, therapy period, age or sex of the patient, and other conditions.
- the dosage varies depending on the administration route, but normally dosage in the range of approximately 0.1 pg to 100 mg/kg may be administered by calculating the amount of active ingredient per dose.
- the method to suppress cardiac hypertrophy of the present invention can be achieved by administering a patient with cardiac hypertrophy or preconditions thereof with the effective amount of a substance that suppresses the functional expression in cardiomyocytes of PKDl, or of nucleic acid that codes for ENH2.
- the method in question may be effectively used as a method to prevent onset of cardiac hypertrophy and development thereof.
- the same substances described in section I. may be cited as substances that suppresses the functional expression in cardiomyocytes of PKDl, or nucleic acids that code for ENH2.
- compositions may be used in the form of pharmaceutical compositions at a dose effective to suppress cardiac hypertrophy together with pharmaceutically acceptable carriers and other additives.
- the formulations, administration routes, and modes of administration, and dosage of the pharmaceutical composition are as previously described in section I .
- Humans and other mammals may be cited as test subjects targeted for administration.
- the mammals in question are not particularly limited, and, concretely, may include rats, mice, hamsters, guinea pigs, dogs, monkeys, cows, horses, sheep, goats, and pigs, etc.
- cardiac hypertrophy is a risk factor inviting heart failure, ischemic heart diseases such as angina pectoris and myocardial infarction, and cardiovascular diseases such as arrhythmia. Consequently, based on the fact that the previously described substances that suppresses the functional expression in cardiomyocytes of PKDl or nucleic acids that code for ENH2 suppress hypercardia in cardiomyocytes, the same substances can be used as drugs to effectively prevent or remedy onset of various types of heart disease caused by cardiac hypercardia.
- heart failure congestive heart failure, acute left-sided heart failure, acute pulmonary heart failure, contractive failure such as cardiogenic shock (attack of myocardial infarction, bradycardia, tachycardia), hypertrophic myocardosis, amyloidosis, systolic pericarditis, and expansive failure such as pericardial tamponade), ischemic heart disease (angina pectoris, myocardial infarction) and arrhythmia may be cited as examples of heart diseases caused by cardiac hypertrophy. The same substances as those described in section I.
- the pharmaceutical composition of the present invention may contain well-known therapeutic drugs for heart disease as necessary.
- the therapeutic drugs for heart disease are not particularly limited, but ⁇ - blockers, anti-hypertensive agents, cardiotonic agents, anti-thrombosis agents, vasodilators, endothelia receptor blockers, calcium channel blockers, phosphodiesterase inhibitors, Angll receptor blockers, cytokine receptor blockers, and gpl30 receptor inhibitors may be cited as examples .
- the formulations and administration routes, modes of administration and dosage of the pharmaceutical compositions are as previously described in section I .
- the method to prevent or remedy heart disease caused by cardiac hypertrophy of the present invention may be carried out by administering to test subjects with heart diseases caused by cardiac hypertrophy or the preconditions thereof the effective amount of a substance that suppresses the functional expression in cardiomyocytes of PKDl or of nucleic acid that codes for ENH2.
- the method in question may be effectively used as a method to prevent cardiac hypertrophy from developing into heart disease for a test subject with cardiac hypertrophy.
- the same substances as those described in section I . may be cited as the substances that suppress the functional expression of PKDl in cardiomyocytes or the nucleic acids that code for ENH2.
- the substances in question may be used in the form of pharmaceutical compositions at a dose effective to prevent or remedy heart diseases caused by cardiac hypertrophy together with pharmaceutically acceptable carriers and other additives.
- the formulations, administration routes, modes of administration, and dosage of the pharmaceutical composition are as previously described in section I .
- the pharmaceutical compositions of the present invention may be coadministered with well-known therapeutic drugs for heart disease as necessary.
- the therapeutic drugs for heart disease in question are not particularly limited, but ⁇ -blockers, anti-hypertensive agents, cardiotonic agents, anti-thrombosis agents, vasodilators, endothelia receptor blockers, calcium channel blockers, phosphodiesterase inhibitors, Angll receptor blockers.
- cytokine receptor blockers and gpl30 receptor inhibitors may be cited as examples.
- the same heart failure, ischemic heart diseases such as angina pectoris and myocardial infarction, and cardiovascular diseases such as arrhythmia described in section III. may be cited as the types of heart disease caused by cardiac hypertrophy.
- the same human or other mammals rats, mice, hamsters, guinea pigs, dogs, monkeys, cows, horses, sheep, goats, and pigs, etc.
- test subjects targeted for treatment may be cited as the test subjects targeted for treatment .
- V. Method to block cardiac hypertrophy signal transduction The previously described method to suppress cardiac hypertrophy and method to prevent or remedy heart disease caused by cardiac hypertrophy may be carried out by suppressing the functional expression of PKDl in cardiomyocytes or by the transient expression of ENH2 within cardiomyocytes. This is based on the fact that suppressing the functional expression of PKDl in cardiomyocytes or the transient expression of ENH2 inhibits either cardiac hypertrophy signal transduction mediated though GPCR or EGF receptor or cardiac hypertrophy signal transduction involving ENH1. For this reason, from a separate point of view, the present invention provides a method to block or suppress the cardiac hypertrophy signal transduction in cardiomyocytes.
- the cardiac hypertrophy signal transduction targeted here is one mediated directly through GPCR or EGF receptor.
- the blocking or suppression of the cardiac hypertrophy signaling may be carried out by administering to the test substance the effective amount of a substance that inhibits functional expression of PKDl in cardiomyocytes or of a nucleic acid that codes for ENH2.
- the test substance in question may be cardiomyocytes or tissues having the same, or may be cultured cardiomyocytes, cultured heart tissue, or cardiomyocytes or heart tissue present in a living body.
- the source of the cardiomyocytes or heart tissue is not particularly at issue, and humans or other mammals (rats, mice, hamsters, guinea pigs, dogs, monkeys, cows, horses, sheep, goats, and pigs, etc.) may be broadly cited.
- the same substances and amounts thereof previously described in section I may be cited as the substances that suppress functional expression of PKDl or a nucleic acid that code for ENH2 and the amounts thereof that are to be administered to the test subjects.
- Substances that block cardiac hypertrophy signal pathway mediated through gpl30 receptors such as cytokine blockers, etc.
- gpl30 receptor inhibitors may be administered in combination with substances that suppress functional expression of PKDl or nucleic acid that code for ENH2. By doing this, it is possible to jointly block cardiac hypertrophy signal pathways different from those mediated through GPCR or EGF receptor.
- Transgenic non-human animals constructed to express protein related to PKDl in the cells of non-human animals .
- mammals such as rats, mice, hamsters, guinea pigs, cows, horses, monkeys, dogs, sheep, goats, and pigs, etc. may be cited as non-human animals.
- the present invention provides a transgenic non-human animal that transiently expresses constitutively active PKDl in cardiomyocytes .
- the transgenic non-human animals in question develop cardiac hypertrophy based on the PKDl in the cardiomyocytes being in the fully active state (phosphorylated) .
- the transgenic non-human animals may be effectively used in histological research on cardiac hypertrophy, in demonstrating the mechanisms of the development into heart disease, and, as animals for screening, in development of cardiac hypertrophy suppressants and preventatives and remedies for heart disease.
- Constitutively active PKDl can be created by deleting the amino acid residue of a specific region of PKDl or by substituting by point mutation, etc.
- constitutively active PKDl may be created by deleting the a PH domain in the amino acid sequence thereof, or by substituting the serines of positions 744 and 748 with glutamic acids; and with mouse derived PKDl, by substituting the serines of positions 744 and 748 with glutamic acids in the amino acid sequence thereof .
- the animal model of cardiac hypertrophy disease is, concretely, a transgenic non-human animal that is in a state capable of expressing the genes that code for constitutively active PKDl in cardiomyocytes under the control of functional DNA such as a promoter, and that based on this the constitutively active PKDl is expressed and produced in cardiomyocytes .
- the present invention provides a transgenic non-human animal that has the functional expression of PKDl in cardiomyocytes knocked out.
- the cardiac hypertrophy signal pathways through GPCR or EGF receptor is blocked because the PKDl in the cardiomyocytes is in the inactive state (non-phosphorylated) , and these animals do not develop cardiac hypertrophy by stimulation mediated through the GPCR or EGF receptor.
- the transgenic non-human animals may be used effectively in understanding the cardiac hypertrophy mechanisms through other cardiac hypertrophy signal pathways than cardiac hypertrophy signal pathways mediated through GPCR or EGF receptor (for example, cardiac hypertrophy signal pathways mediated through gpl30 receptor) , and in understanding the development into heart disease.
- the transgenic non-human animals with the functional expression of PKDl in cardiomyocytes knocked out can be created by expressing dominant negative PKDl in the cardiomyocytes thereof.
- Dominant negative PKDl may be created either by deleting the amino acid residue of a specified region of PKDl (for example, the ATP binding region or the phosphorylation active loop) , or by using point mutation to substitute a specified site (for example, the ATP binding site or the phosphorylation active loop site).
- the dominant negative PKDl may be created by substituting the lysine at position 612 in the amino acid sequence thereof with tryptophan, substituting the lysine of position 618 with asparagine, substituting the aspartic acid of position 733 with alanine, or substituting the serines of positions 738 and 742 with alanines.
- the dominant negative PKDl may be created by substituting the lysine of position 618 in the amino acid sequence thereof with methionine, or substituting the serines of positions 744 and 748 with alanines.
- the transgenic non-human animals in question are, concretely, animals that are in a state of being able to express genes that code for dominant negative PKDl under the control of functional DNA such as a promoter in cardiomyocytes, and thereby the dominant negative PKDl is expressed and produced in the cardiomyocytes.
- the method for producing these transgenic non-human animals is generally described in US Patent No. 4873191, Brister et al., Proc. Natl. Acad. Sci. USA, 82, p.
- the present invention provides a method for screening substances that can suppress the functional expression of PKDl in cardiomyocytes.
- a preferable substance is one that has an action to suppress the functional expression of PKDl in cardiomyocytes .
- the substance may be expected to be able to suppress the onset or development of cardiac hypertrophy by blocking or suppressing hypertrophy signal transduction mediated through GCPR in cardiomyocytes. Further, according to the substance, it may be expected that heart disease caused by cardiac hypertrophy can be prevented or remedied. That is, the present invention provides a method for screening the active ingredients of cardiac hypertrophy suppressants, or agents to prevent or remedy heart disease caused by cardiac hypertrophy.
- the screening method in question basically comprises investigating substances that have an action to suppress functional expression of PKDl in cardiomyocytes, but concretely, the following screening methods (1) to (4) may be cited as examples .
- (1) Method for screening an active ingredient of cardiac hypertrophy suppressants including the following steps: (a) bringing a test substance into contact with cells that can express PKDl; (b) measuring the levels of expression of PKDl in the aforementioned cells, and comparing with the level of PKDl expression in contrast cells that are not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as an active ingredient of cardiac hypertrophy suppressants the test substance which, when brought into contact with cells, lowered the level of expression of PKDl as compared to the contrast cells .
- the cells used here are in a state capable of expressing PKDl genes, and the derivation of the cells is not particularly limited.
- these are cells in a state capable of expressing PKDl genes derived from humans or derived from mammals other than humans.
- cardiomyocytes or skeletal muscle cells derived from humans or from mammals other than humans may be cited, and cultured cells isolated and prepared from the heart or skeletal muscle may be suitably used.
- Tissue that is an aggregate of cells may also be included in the related category.
- test substances are not particularly limited, but are nucleic acids, peptides, proteins, organic compounds or inorganic compounds.
- the screening may be carried out by bringing these test substances or substances containing them (for example, cell extracts, including expression products of gene libraries, etc.) into contact with the target cells.
- the conditions for contact between the cells and the test substance adopted when screening are not particularly limited, but it is preferable to select culture conditions that can express the desired gene without killing the cell (the same applies in the screening methods below) .
- a polynucleotide and/or a complementary polynucleotide thereof that has at least 15 bases continuous to the base sequence of the PKDl gene as a primer or probe, it is possible to measure the level of PKDl expression by employing a well-known method such as Northern blot, RT-PCR, in situ hybridization analysis, differential hybridization, DNA chip, or RNase protection assay.
- the expression level of PKDl may also be evaluated by measuring the amount of PKDl (protein) expressed and produced. In this case, the PKDl produced is detected and assayed by a well-known method such as Western blot using as a marker an antibody that recognizes PKDl.
- Selection of the active ingredient (candidate substance) of a cardiac hypertrophy suppressant or an agent to prevent or remedy heart disease caused by cardiac hypertrophy by the screening method may be conducted by using as an index the fact that the level of PKDl expression in cells brought into contact with a test substance becomes lower than the level of PKDl expression in cells that have not been brought into contact with the test substance.
- PKDl is a component that plays a central role in cardiac hypertrophy signal transduction mediated through GPCR or EGF receptor.
- the substance that suppresses the expression and production of PKDl selected by the aforementioned screening can prevent or suppress the cardiac hypertrophy signal cascade, and therefore can be used as an active ingredient of a cardiac hypertrophy suppressant or as an active ingredient of an agent to prevent or remedy heart disease caused by cardiac hypertrophy.
- Method for screening an active ingredient of cardiac hypertrophy suppressants including the following steps : (a) bringing a PKDl activator and a test substance into contact with cells that can express PKDl; (b) measuring the activity of PKDl in the aforementioned cells, and comparing with the activity of PKDl in contrast cells that are not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as an active ingredient of cardiac hypertrophy suppressants the test substance which, when brought into contact with cells, lower the activity of PKDl as compared to the contrast cells. Using the steps, it is possible to obtain substances that suppress the expression and production of PKDl or that inhibit PKDl activity.
- PKDl activators may be ones that can make PKDl fully active (phosphorylation) , and typical examples include phorbol esters such as TPA (12-0- tetradecanoylphorbol 13-acetate) ,diacylglycerol (DG), and PKC (for exmaple, PKC ⁇ ).
- TPA (12-0- tetradecanoylphorbol 13-acetate
- DG diacylglycerol
- PKC for exmaple, PKC ⁇
- the measurement of PKDl activity may be conducted by evaluating the phosphorylating ability of PKDl (for example, with human derived PKDl, the activity for phosphorylating position Ser-916 of the amino acid sequence) .
- the method thereof is not particularly limited, but concretely, the method of evaluating phosphorylating ability (phosphorylation assay) for a specific substrate peptide (for example, Syntide-2 [APLARTLSVAGLPGKK]) may be cited as an example.
- the phosphorylation assay in question may be conducted by following the methods explained in the experiments .
- selection of the active ingredient (candidate substance) of a cardiac hypertrophy suppressant or an agent to prevent or remedy heart disease caused by cardiac hypertrophy may be conducted by using as an index the fact that the PKDl activity in cells brought into contact with a test substance becomes lower than the PKDl activity in cells that have not been brought into contact with the test substance.
- PKDl is an important component in cardiac hypertrophy signal transduction, and a downstream cascade is activated through PKDl activity, thereby inducing cardiac hypertrophy. Consequently, a substance selected by the aforementioned screening method can inhibit or suppress the cardiac hypertrophy signaling, and can be used as an active ingredient of a cardiac hypertrophy suppressant or as an active ingredient of an agent to prevent or remedy heart disease caused by cardiac hypertrophy.
- Method for screening an active ingredient of cardiac hypertrophy suppressants including the following steps: (a) bringing a test substance and a cardiac hypertrophy inducer that stimulate GPCR or EGF receptor into contact with cardiomyocytes; (b) measuring the PKDl activity, localization of phosphorylated PKDl in sarcomere Z-discs, or the intermolecular distance of PKC ⁇ and PKDl in the aforementioned cardiomyocytes, and comparing with the corresponding PKDl activity, localization or intermolecular distance in contrast cardiomyocytes that were brought into contact with hypercardia inducer only; and (c) based on the comparative results of (b) above, selecting as an active ingredient of cardiac hypertrophy suppressants the test substance which, when brought into contact with the cardiomyocytes, lower the activity of PKDl, lower the localization of phosphorylated PKDl in sarcomere Z-discs, or increase the intermolecular distance of PKC ⁇ and PKDl as compared to
- Cultured cells suitably isolated and prepared from humans or from mammals other than humans may be used as the cells in question. Tissue that is an aggregate of cardiomyocytes may also be included in this category.
- Substances known to induce cardiac hypertrophy mediated through GPCR or EGF receptor may be cited as cardiac hypertrophy inducers that stimulate GPCR or EGF receptor.
- typical of the former are Angll, endothelin-1, and NE; and of the latter, epidermal growth factor (EGF).
- the desired substance is selected by using as an index at least one of PKDl activity in cardiomyocytes, localization of phosphorylated PKDl in sarcomere Z-discs, or intermolecular distance of PKC ⁇ and PKDl.
- the method described in (2) above may be used as the measurement method of PKDl activity.
- the localization of phosphorylated PKDl in sarcomere Z-discs can be investigated by staining the cardiomyocytes with a regent that can specifically label and detect phosphorylated PKDl (fully active PKDl), and then observing the behavior of phosphorylated PKDl in cardiomyocytes using a detection method corresponding to that reagent.
- Antibodies that specifically recognize and bond with phosphorylated PKDl may be cited as regents that can specifically label and detect phosphorylated PKDl .
- examples include antibodies to peptides having the amino acid sequence 912 to 918 (here, position Ser-916 is phosphorylated) of human derived PKDl (anti-fully active PKDl antibodies), and these antibodies will be used in the experiments.
- the method may be cited of treating cardiomyocytes with an antibody specific to ⁇ -actinin sarcomere, an antibody to the aforementioned phosphorylated PKDl (fully active PKDl), and a fluorescent or chemilumines ⁇ ent reagent, and then conducting a differential analysis of the fluorescent image or chemiluminescent image of the cells obtained.
- an antibody specific to ⁇ -actinin sarcomere an antibody to the aforementioned phosphorylated PKDl (fully active PKDl)
- a fluorescent or chemilumines ⁇ ent reagent a fluorescent or chemilumines ⁇ ent reagent
- an active ingredient (candidate substance) of cardiac hypertrophy suppressants or agents to prevent or remedy heart disease caused by cardiac hypertrophy based on the screening method may be conducted by using as an index as follow: - the fact that PKDl activity in cardiomyocytes that have been brought into contact with a cardiac hypertrophy inducer and a test substance is lower than the PKDl activity in contrast cardiomyocytes that have been brought into contact with cardiac hypertrophy inducer only (that is, not brought into contact with the test substance); - the fact the localization of phosphorylated PKDl in sarcomere Z-discs in cardiomyocytes that have been brought into contact with a cardiac hypertrophy inducer and a test substance is lower than the localization of phosphorylated PKDl in sarcomere
- PKDl is an important component in cardiac hypertrophy signal transduction, and a downstream cascade is activated through PKDl activation, thereby inducing cardiac hypertrophy. In addition, when activated, PKDl moves to sarcomere Z-discs and becomes localized there. Further, PKC ⁇ is a direct activator of PKDl, and during cardiac hypertrophy signaling, PKC ⁇ and PKDl form a complex. Consequently, a substance selected by the aforementioned screening methods has an action to prevent or suppress cardiac hypertrophy signaling, and can be used as an active ingredient of a cardiac hypertrophy suppressant or as an active ingredient of an agent to prevent or remedy heart disease caused by cardiac hypertrophy.
- Method for screening an active ingredient of cardiac hypertrophy suppressants including the following steps: (a) bringing a test substance into contact with cardiomyocytes that can express constitutively active PKC ⁇ or constitutively active PKDl; (b) measuring the PKDl activity, localization of phosphorylated PKDl (fully active PKDl) in sarcomere Z- discs, or the intermolecular distance of PKC ⁇ and PKDl in the aforementioned cardiomyocytes, and comparing with the PKDl activity, localization or intermolecular distance in corresponding contrast cardiomyocytes that were not brought into contact with the test substance; and (c) based on the comparative results of (b) above, selecting as an active ingredient of cardiac hypertrophy suppressants the test substances which, when brought into contact with the cardiomyocytes, lower the activity of PKDl, lower the localization of phosphorylated PKDl in sarcomere Z-discs, or increase the intermolecular distance of PKC ⁇
- cardiomyocytes prepared to be able to express constitutively active PKC ⁇ or constitutively active PKDl are used. Cardiomyocytes that can express constitutively active PKDl are able to express PKDl in a fully active state (phosphorylated) without stimulation by cardiac hypertrophy inducers. Cardiomyocytes that can express constitutively active PKC ⁇ are able to fully activate (phosphorylate) PKDl based on activation of PKC ⁇ without stimulation by cardiac hypertrophy inducers.
- constitutively active PKC ⁇ has the psuedosubstrate region of the N-terminal of PKC ⁇ deleted, or has a specified amino acid residue substituted by point mutation (Sch ⁇ nwasser, D.C., et al., Mol. Cell. Biol. 18, p. 790-798, 1998).
- protein with deleted region 156 to 162 in the amino acid sequence of human derived PKC ⁇ may be cited as a concrete example.
- constitutively active PKDl has the amino acid residue of a specific region of PKDl deleted or substituted by a point mutation, etc..
- cardiomyocytes that can express the constitutively active PKC ⁇ and the constitutively active PKDl can be created by introducing genes that code for these proteins into cardiomyocytes (including culture cells) derived from humans or other mammals following ordinary genetic recombinant technologies.
- Selection of the active ingredient (candidate substance) of a cardiac hypertrophy suppressant or an agent to prevent or remedy heart disease caused by cardiac hypertrophy based on the screening method in question may be conducted by using as an index as follows: - the fact that PKDl activity in cardiomyocytes that have been brought into contact with a test substance is lower than the PKDl activity in contrast cardiomyocytes that have not been brought into contact with the test substance; - the fact that the localization of PKDl in sarcomere Z-discs in cardiomyocytes that have been brought into contact with a test substance is lower than the localization of PKDl in sarcomere Z-discs in contrast cardiomyocytes that have not been brought into contact with the test substance; or - the fact that the intermolecular distance of PKC ⁇ and PKDl in cardiomyocytes that have been brought into contact with a test substance is longer than the intermolecular distance of PKC ⁇ and PKDl in contrast cardiomyocytes that have not been
- Candidate substances selected by the above screening methods may also be screened using non-human animal models of cardiac hypertrophy or of diseases caused cardiac hypertrophy.
- the previously described transgenic non-human animals of the present invention that transiently expressed constitutively active PKDl may be cited as examples of the said non-human animal models .
- the screening using the non-human animal models may be carried out according to the following steps: (a) administering a test substance to a transgenic non-human animal (non-human animal model of cardiac hypertrophy or of disease caused by cardiac hypertrophy) with transient expression of constitutively active PKDl; (b) measuring the extent of cardiac hypertrophy in the aforementioned non-human animal, and comparing with the extent of cardiac hypertrophy in contrast transgenic non-human animal that were not administered the test substance; and (c) based on the comparative results of (b) above, selecting test substance that reduced or suppressed cardiac hypertrophy of the non-human animal as cardiac hypertrophy suppressants .
- the extent of cardiac hypertrophy may be determined by histologi ⁇ al evaluation of the heart, clinical evaluation (echocardiogram, Doppler ultrasound exam, coronary artery imaging, chest X-ray, electrocardiogram, etc.), or by evaluation from the level of ANP expression in cardiomyocytes, which is a marker of cardiac hypertrophy.
- pharmacological tests using non-human animals with cardiac hypertrophy or diseases caused by cardiac hypertrophy, safety tests, and clinical trials on patients (human) with cardiac hypertrophy or diseases caused by cardiac hypertrophy, or patients (human) with the preconditions of cardiac hypertrophy may also be conducted; and by conducting these tests, it is possible to select a more practical active ingredient for a composition for suppressing cardiac hypertrophy or for an agent to prevent or remedy heart disease caused by cardiac hypertrophy.
- substances selected in this way may be industrially manufactured by chemical synthesis, biological synthesis (including fermentation) or genetic manipulation corresponding to the type of substance, and then used in the preparation of pharmaceutical compositions to suppress cardiac hypertrophy or pharmaceutical compositions to prevent or remedy heart disease.
- Angll Angiotensin II
- ANF Arterial natriuretic factor
- BrDU 5-bromo-2 ' -deoxyuridine
- BSA Bovine serum albumin
- Constitutively active DN Dominant negative FBS: Fetal bovine serum
- GFP Green fluorescent protein
- G protein Guanine nucleotide-binding protein
- KD Kinase dead
- LIF Leukemia inhibitory factor
- NE Norepinephrine ET1 Endothelin 1
- EGF Epidermal growth factor
- bFGF Basic fibroblast growth factor
- NRC Neonatal rat cardiomyocytes
- PBS Phosphate-buffered saline
- PKC Protein kinase C
- PLC Phospholipase C
- TPA 12-0-tetradecanoylphorbol 13-acetate
- DMEM Dulbecco ' s modified
- the human derived PKDl is initially made catalytically active by phosphorylation of the active loop residues (Ser-744, Ser-748) using phosphoinositide- dependent kinase 1 (PDKl). Then the C-terminal region (Ser-916) undergoes auto-phosphorylation, and the entire molecule becomes the active type (in the present description, this is called the "fully active type"). Accordingly, phosphorylation of Ser-916 site of PKDl provides the optimum indication to confirm that PKDl is activated in vivo (fully active PKDl) (Matthews S.A., et al., J. Biol. Chem. 274, p. 26543-26549).
- the antibodies to the phosphorylated Ser-916 site are antibodies effective for specifically detecting fully active PKDl present in cardiomyocytes.
- pTB701-HA vector A vector for expressing fused protein with HA epitope at the NH 2 terminal in mammal cells . The base sequence that codes for HA epitope is inserted into downstream of the SV40 early promoter in the expression vector pTB701.
- CA-PKC Constitutively active PKC mutant
- Dominant negative PKC mutant This is in the inactive state by mutating (point mutation) of Lys at the ATP binding site into Met (Kuroda, S., et al., J. Biol. Chem. 271, p. 31029-31032, 1996; Kuroda, S., et al., J. Cell Biol. 144, p. 403-411, 1999).
- ⁇ PKC ⁇ l-HA dominant negative mutant (K371M PKC ⁇ l- HA) Prepared using site-directed mutagenesis to substitute Met for the Lys necessary for ATP binding at position 371 of rat derived PKC ⁇ l.
- ⁇ PKC ⁇ -HA dominant negative mutant (K281M PKC ⁇ -HA) Prepared using site-directed mutagenesis to substitute Met for the Lys necessary for ATP binding at position 281 of rat derived PKC ⁇ .
- ⁇ PKC ⁇ -HA dominant negative mutant (K440M PKC ⁇ -HA) Prepared using site-directed mutagenesis to substitute Met for the Lys necessary for ATP binding at position 440 of rat derived PKC ⁇ .
- EXPERIMENT 1 Expression of PKDl in neonatal rat cardiomyocytes and localization thereof Western blotting is used to investigate the state of expression of PKDl and PKD2 in neonatal rat cardiomyocytes (NRC), as well as the intracellular localization (distribution) thereof.
- PKD2 is a gene product that differs from PKDl (Sturany, S., et al., J. Biol. Chem. 276, p. 3310-3318, 2001).
- NRC was further treated with TPA, and the expression of PKDl and PKD2 in the treated NRC and the intracellular localization thereof were studied in the same manner.
- TPA is one type of phorbol ester known to be an activator of PKC and PKD (Kikkawa U. , et al.. Adv. Cyclic Nucleotide Protein Phosphorylation Res., 17, p. 437-42, 1984; Valverde AM, et al. , Proc. Natl. Acad. Sci. USA, 30, 91(18), p. 8572-6, 1994).
- TPA also induces cardiac hypertrophy (Kinnunen P., et al., Br. J. Pharmacol., 102(2), p.
- the hearts were removed from 30 neonate rats, then rinsed of blood with phosphate-buffered physiological saline (PBS, containing no Mg 2+ or Ca 2+ ) , removed the blood vessels, divided into 4 pieces, and then rinsed again with PBS.
- PBS phosphate-buffered physiological saline
- 0.3 g of the heart tissue was processed in 10 mL of 0.1 w/v% collagenase type I (Wako Pure Chemical Industries Ltd. ) aqueous solution for 10 to 15 minutes at 37°C, and the cardiomyocytes were separated and dispersed in the aqueous solution.
- This collagenase treatment was repeated 2 more times using fresh collagenase aqueous solution.
- the treatment solution was centrifugally separated, the resultant precipitate were suspended in 10 mL of culture medium (DMEM+10% FBS), and the suspension was filtrated with sterilized Kimwipes set in a sterile filter unit
- Cardiomyocytes (dispersed cells).
- the cardiomyocytes obtained were moved to a tissue culture plate (manufactured by Falcon) coated with collagen, and cultured for 50 minutes, at 37° C under a 5% C0 2 concentration, and utilizing the difference in the adhesive strength of the cells, the fibroblast cells co- present in the cardiomyocytes were removed by adhering to the bottom of a culture plate coated with collagen (a differential adhesion technique) .
- the cardiomyocytes present in the supernatant were used as neonatal rat cardiomyocytes (NRC).
- the NRC obtained was stored in DMEM containing 0.45% glucose, 10% (v/v) fetal bovine serum (FBS), 2 mM L- glutamine, 100 units/mL penicillin, 100 ⁇ g/mL streptomycin, and 20 ⁇ M 5-bromo-2" -deoxyuridine (BrDU: Sigma).
- ⁇ anti-PKDl/2 monoclonal antibody manufactured by LC Laboratories
- ⁇ anti-fully active PKDl polyclonal antibody ⁇ anti- inactive PKDl polyclonal antibody
- ® anti-sarcomeric- ⁇ - actinin monoclonal antibody clone EA-53: manufactured by SIGMA
- ⁇ anti-H3 histon mouse monoclonal antibody 05-499: manufactured by UpState Biotechnology
- TPA treated substance cytoplasm fraction and cell membrane fraction
- untreated substance cytoplasm fraction and cell membrane fraction
- anti-mouse or anti-rabbit IgG bound with horseradish derived peroxidase manufactured by Amersham Pharmacia
- Fig. 2 Results The results are indicated in Fig. 2. Nearly the same amount of ⁇ -actinin and histone H3 was detected in the various samples (cytoplasm fraction: untreated substance (None) and TPA treated substance (TPA) , and membrane fraction: untreated substance (None) and TPA treated substance (TPA)). This fact means that nearly equivalent amounts of cardiomyocytes derived protein were present in every lane.
- Fig. 2 demonstrate that only PKDl was present in cardiomyocytes, and that PKD2 was not present. (The present inventors have already used the same method to confirm that PKD3 is not present in cardiomyocytes .
- EXPERIMENT 2 Behavior of fully active PKDl in cardiomyocytes NRC prepared by a method similar to the method as described in (1) of Experiment 1 was moved to a glass culture plate (35 mm diameter) coated with poly-L-lysine, and was cultured over night (5% C0 2 concentration, 37° C) in DMEM without blood serum (manufactured by Nacalai Tesque). TPA was added to this to make a final concentration of 20 nM, and this was cultured a further 18 hours (5% C0 2 concentration, 37° C) (approximately lxlO 3 cells).
- the cells obtained were rinsed 2 times with PBS, fixed by treating with 4 w/v% paraformaldehide for 30 minutes at room temperature, treated by soaking in PBS containing 0.25 v/v% Triton X- 100 for 30 minutes at 4° C, and then incubated in blocking buffer solution (PBS containing 3 w/v% BSA, 2 v/v% FBS, 1 v/v% normal goat blood serum, and 0.03 v/v% Triton X-100).
- blocking buffer solution PBS containing 3 w/v% BSA, 2 v/v% FBS, 1 v/v% normal goat blood serum, and 0.03 v/v% Triton X-100.
- the cells obtained were incubated at 4° C for 16 hours in blocking buffer solution containing antibodies (anti- fully active PKDl polyclonal antibody, anti-inactive PKDl polyclonal antibody, and anti-sarcomeric- ⁇ -actinin monoclonal antibody). This was rinsed 2 times in PBS, moved into PBS containing 0.3 v/v% Cy3-labeled anti-mouse IgG antibody, and 0.3 v/v% Cy2-labeled anti-rabbit IgG antibody (second antibody) (both manufactured by Amersham Pharmacia), and incubated for 1 hour at room temperature. The fluorescent signals of the cells were observed by a confocal laser scanning microscope LSM5 Pascal (manufactured by Carl Zeiss Inc.).
- Fig. 3A Untreated NRC (None), which was not treated with TPA, was labeled with antibodies in the same manner as a contrast, and the results of observing the cell luminescence signals by confocal laser microscope (LSM5 Pascal) are indicated in Fig. 3B.
- LSM5 Pascal confocal laser microscope
- Figs As is clear by comparing Figs .
- sarcomere structures were formed in TPA-treated I cardiomyocytes (visualization of Z-discs), confirming that cardiac hypertrophy was induced.
- the upper middle image of Fig. 3A was obtained by treating cardiomyocytes with anti-inactive PKDl polyclonal antibody and a second antibody (fluorescent color labeling antibody), and the lower middle image of Fig. 3A was obtained by treating with anti-fully active PKDl polyclonal antibody and a second antibody (fluorescent color labeling antibody) .
- the upper middle image indicates the intracellular localization of inactive PKDl
- the lower middle image indicates the intracellular localization of fully active PKDl .
- NE is a cardiac hypertrophy inducer that acts on ⁇ - adrenaline-like receptors, and in the experiment below, NE was used along with propranol to block ⁇ -adrenergic receptor activity.
- NRC prepared by the same method as described above in (1) of Experiment 1 was moved to a glass culture plate (35 mm diameter) coated with poly-L- I lysine, and was cultured over night (5% C0 2 concentration, 37° C) in DMEM without blood serum (manufactured by Nacalai Tesque) .
- GF109203X is a selective PKC inhibitor that does not act on PKD (Zugaza J.L., et al.. The EMBO J. , 1996, 15, p. 6220-6230).
- the cells were rinsed 2 times with PBS, fixed by treating with 4 w/v% paraformaldehide for 30 minutes at room temperature, treated by soaking in PBS containing 0.25 v/v% Triton X-100 for 30 minutes at 4° C, and then incubated in blocking buffer solution (PBS containing 3 w/v% BSA, 2 v/v% FBS, 1 v/v% normal goat blood serum, and 0.03 v/v% Triton X-100).
- blocking buffer solution PBS containing 3 w/v% BSA, 2 v/v% FBS, 1 v/v% normal goat blood serum, and 0.03 v/v% Triton X-100).
- the cells obtained were incubated at 4° C for 16 hours in blocking buffer solution containing antibodies (anti-fully active PKDl polyclonal antibody, anti-inactive PKDl polyclonal antibody, and anti-sarcomeric- ⁇ -actinin monoclonal antibody). This was rinsed 2 times in PBS, moved into PBS containing 0.3 v/v% Cy3-labeled anti-mouse IgG antibody, and 0.3 v/v% Cy2-labeled anti-rabbit IgG antibody (second antibody) (both manufactured by Amersham Pharmacia), and incubated for 1 hour at room temperature. The fluorescent signals of the cells were observed by a confocal laser scanning microscope LSM5 Pascal (manufactured by Carl Zeiss Ltd.
- PKDl was fully activated (phosphorylated) , and its movement to the vicinity of the sarcomere Z-discs in the cardiomyocytes was observed.
- the inactive PKDl remained in the nuclear vicinity of the cardiomyocytes in both ⁇ NE and ⁇ Angll cases. Meanwhile, as indicated in Fig.
- PKDl is a component of a cardiac hypertrophy signal transduction mediated through the seven transmembrane-spanning heterotrimeric G protein- coupled receptor (GCPR) signaling pathway, and is deeply- related to the cardiac hypertrophy onset mechanism through this pathway.
- GCPR G protein- coupled receptor
- EGF cardiac hypertrophy
- GPCR receptor-type tyrosine kinase
- EXPERIMENT 4 Control of PKDl fully activation ( hosphorylation)
- PKDl phosphorylate Syntide-2
- APLARTLSVAGLPGKK a selective substance for PKDl
- PKDl activity Valverde, A.M., et al., Proc. Natl. Acad. Sci. USA, 91, 1994, p. 8572-8576. Accordingly, the phosphorylation activity of PKDl within cardiomyocytes with induced cardiac hypertrophy was evaluated based on the ability to phosphorylate Syntide-2.
- immunoprecipitation kinase assays using Syntide-2 as a substrate were conducted on the following NRC samples: NRC samples with cardiac hypertrophy induced by treating for 20 minutes respectively with ⁇ 100 nM TPA, ⁇ 100 ⁇ M NE, and ⁇ 20 nM LIF, and NRC samples treated for 20 minutes respectively with ⁇ 400 nM GF109203X (PKC inhibitor), ⁇ 20 nM TPA + 400 nM GF109203X, ⁇ 100 ⁇ M NE + 400 nM GF109203X, and ⁇ 20 nM LIF + 400 nM GF109203X.
- the phosphorylation activity of PKDl present in the various NRC samples was measured.
- the phosphorylation activity of PKDl present in NRC that was not treated with anything (untreated NRC) was described and measured in the same way.
- ⁇ 100 nM TPA, ⁇ 100 ⁇ M NE (containing 2 ⁇ M propranol), ⁇ 20 nM LIF, ⁇ 400 nM GF109203X (PKC inhibitor), ⁇ 20 nM TPA + 400 nM GF109203X, ⁇ 100 ⁇ M NE + 400 nM GF109203X, and ⁇ 20 nM LIF + 400 nM GF109203X were added respectively, and treated for 20 minutes.
- the cells obtained were treated with Lysis buffer solution A, and incubated for 60 minutes on ice together with anti-fully active PKDl polyclonal antibody.
- PKDl-anti-PKDl antibody complex Protein G Sepharose 4B bound PKDl-anti-PKDl antibody complex
- the PKDl immunoprecipitate was rinsed 1 time in Lysis buffer solution A, and further rinsed 2 times with Lysis buffer solution A not containing NaF.
- the PKDl was eluted from PKDl immunoprecipitate obtained by incubating in Lysis buffer solution A not containing NaF together with 100 ⁇ L of 0.5 mg/mL immunizing peptide.
- the immunizing peptide is an antigen peptide used in order to immunize test animals to create anti-fully active PKDl polyconal antibody.
- PKDl When incubating this peptide with protein G Sepharose 4B bound PKDl-anti-PKDl antibody complex, the aforementioned antigen peptide and the anti-PKDl antibody bond, and as a result, PKDl can be freed and obtained.
- the eluted PKDl (10 ⁇ L) was incubated for 5 minutes at 30° C together with assay mixed solution (15 ⁇ L
- Tris/MgCl 2 100 mM Tris, 100 mM MgCl 2 ) , 5 ⁇ L ATP (800 ⁇ M) , 0.2 ⁇ L 32 ⁇ -ATP, and 40 ⁇ g Syntide ⁇ 2).
- Results are indicated in Fig. 8. Indicated from the left in the bar graph are the levels of phosphorylation activity of PKDl present in untreated NRC (negative control), and in NRC treated with ⁇ 100 nM TPA, ⁇ 100 ⁇ M NE (containing 2 ⁇ M propranol), ⁇ 20 nM LIF, ® 400 nM GF109203X (PKC inhibitor), ⁇ 100 nM TPA + 400 nM GF109203X, ⁇ 100 ⁇ M NE + 400 nM GF109203X, and ⁇ 20 nM LIF + 400 nM GF109203X.
- the levels of phosphorylation activity of PKDl present in the various types of NRC are indicated in the relative percentages (%) to when the measured level of the negative, control (CPM, 32 P) is taken as 100%.
- the PKDl present in NRC treated by either TPA or NE both has notably higher phosphorylation activity than the PKDl present in untreated NRC (negative control) or in NRC treated with LIF.
- TPA cardiac hypertrophy inducers
- GF109203X PKC inhibitor
- phosphorylation activity was measured in the same way for PKDl present in cardiomyocytes treated with NE using wild type NRC, and for PKDl present in cardiomyocytes untreated with NE using wild type NRC, as a negative contorol.
- Results are indicated in Fig. 9. Indicated from the left in the bar graph are the levels of phosphorylation activity of PKDl present in the following cardiomyocytes: ⁇ untreated wild type NRC (negative control), ⁇ wild type NRC + NE treatment, ⁇ NRC- expressed kinase dead PKC ⁇ + NE treatment, ® NRC- expressed kinase dead PKC ⁇ l + NE treatment, ⁇ NRC- expressed kinase dead PKC ⁇ + NE treatment, ⁇ NRC- expressed kinase dead PKC ⁇ + NE treatment, and ⁇ NRC- expressed kinase dead PKC ⁇ + NE treatment. As indicated in Fig.
- intrinsic PKDl activity in the cells is the same level as PKDl activity of the untreated wild type NRC (negative control) only when kinase dead PKC ⁇ is introduced into the NRC (specifically, only NRC with suppressed PKC ⁇ activity) , and demonstrates that PKCl was not fully activated (phosphorylated) even when inducing cardiac hypertrophy with NE.
- PKC ⁇ is the activator positioned upstream of PKDl in cardiac hypertrophy signaling pathway in cardiomyocytes .
- EXPERIMENT 6 Interaction of PKC ⁇ and PKDl
- the experimental results above demonstrate that activation of PKC ⁇ and PKDl are related to cardiac hypertrophy signal transduction mediated through GPCR, and that PKC ⁇ is an activator positioned upstream of PKDl. Therefore, the interaction between PKC ⁇ and PKDl in cardiomyocytes was studied next. Specifically, we studied the interaction between PKC ⁇ and PKDl in NRC with cardiac hypertrophy induced by NE (100 ⁇ M) .
- anti-PKD ⁇ antibody immunoprecipitate sample was collected.
- 1 mL cell extract (cell lysate) of untreated NRC was obtained in the same way, and anti-PKD ⁇ antibody immunoprecipitate sample and anti-PKDl antibody immunoprecipitate sample were prepared.
- Western blotting was conducted on the anti-PKC ⁇ antibody immunoprecipitate samples and the cell extract (cell lysate) obtained for the various NRC by using anti- PKD1/2 monoclonal antibody as the first antibody, and anti-mouse or anti-rabbit IgG bound with horseradish derived peroxidase (manufactured by Amersham Pharmacia) as the second antibody.
- the results relating to the anti-PKD ⁇ antibody immunoprecipitate samples are indicated in the first (upper) column of Fig. 10, and the results relating to the cell lysate are indicated in the third column.
- Western blotting was conducted on the anti-PKDl/2 antibody immunoprecipitate samples and cell lysate obtained from the various NRC using anti-PKC ⁇ monoclonal antibody as the first antibody and the same second antibody as above.
- the results relating to the anti- PKDl/2 antibody immunoprecipitate samples are indicated in the second column of Fig. 10, and the results relating to the cell lysate are indicated in the forth column of Fig. 10.
- anti- PKDl/2 antibody immunoprecipitate samples specifically, samples containing PKDl
- anti-PKD ⁇ antibody immunoprecipitate samples specifically, samples containing PKC ⁇
- NE-treated NRC reacted with anti-PKC ⁇ antibodies and anti-PKDl/2 antibodies, respectively.
- This fact demonstrates that complex of PKC ⁇ and PKDl were formed in the NRC with induced cardiac hypertrophy. This was not observed in NRC not treated with NE, and therefore appears to indicate that PKC ⁇ activated in the process of generating cardiac hypertrophy (cardiac hypertrophy signaling process) reacts with PKDl and forms a complex.
- EXPERIMENT 7 Inducement of cardiac hypertrophy by fully active PKDl
- PKDl was fully activated (phosphorylated) in cardiomyocytes in which cardiac hypertrophy had been caused.
- PKDl phosphorylating of PKDl (whether or not fully active PKDl induces cardiac hypertrophy) .
- a plasmid having DNA coding for GFP fused-constitutively active PKDl (GFP-PKD1/CA) , or as a control, DNA coding for GFP (GFP) was introduced into NRC by using the transfection reagent (Duo Feet: Q-biogen) according to the instruction manual, to obtain transformed NRC.
- the cells obtained above (transformants) were incubated at 4° C for 16 hours in blocking buffer solution containing antibodies (anti-sarcomeric- ⁇ -actinin monoclonal antibodies) .
- 11A indicates that fully active PKDl spontaneouly localized at Z-discs, which suggests the possibility that the fully active PKDl alone induces the formation of Z-discs (2) a plasmid having DNA coding for constitutively active PKC ⁇ (PKC ⁇ /CA) by electroporation using the Amaxa ele ⁇ troporator with the Rat Cardiomyocyte-Neonatal Nucleofector kit (manufactured by Amaxa GmbH) according to the manufacture's instructions.
- the cells obtained above (transformants) were processed by the same manner as described in (1), the luminescent signals of the cells were observed by a confocal laser microscope LSM5 Pascal (manufactured by Carl Zeiss, Ltd.). The results are indicated in Fig. 11B.
- Fig. 11B indicates that active PKC ⁇ alone spontaneouly translocated at Z-discs.
- EXPERIMENT 8 Relationship between active PKC and the inducement of cardiac hypertrophy The identification the PKC isoforms (PKC ⁇ , PKC ⁇ l, and PKC ⁇ ; these are the main PKCs in the heart) that induce , cardiac hypertrophy was attempted, using various PKC expression plasmids. Concretely, in a similar manner to Experiment 7, NRC was transformed by introduction of an expression vector having DNA coding for constitutively active PKC mutant (CA-PKC ⁇ , CA-PKC ⁇ l, or CA-PKC ⁇ ) or dominant negative PKC mutant (K440M PKC ⁇ ) .
- Panel A indicates image of NRC in which constitutively active PKC ⁇ (CA-PKC ⁇ ) was introduced;
- panel B indicates image of NRC in which constitutively active PKC ⁇ l (CA-PKC ⁇ l) was introduced;
- panel C indicates image of NRC in which ) constitutively active PKC ⁇ (CA-PKC ⁇ ) was introduced;
- panel D indicates image of NRC in which dominant negative PKC ⁇ (K440R PKC ⁇ ) was introduced, and the cells were treated with 100 ⁇ M of NE (induced cardiac hypertrophy treatment);
- panel E indicates image of NRC in which dominant negative PKC ⁇ (K440R PKC ⁇ ) was introduced, and the cells were treated with 20 nM of LIF (induced cardiac hypertrophy treatment) .
- EXPERIMENT 9 Activate PKC ⁇ and fully activate PKD that induce cardiac hypertrophy
- the levels of expression of arterial natriuretic factors (ANF) (hypertrophy markers: Tsuchimochi H., et al. , Lancet, 1987 Aug 8. 2 (8554) p. 336-7) were compared for various types of transformed NRC. Concretely, in a similar manner to Experiment 7, various types of transformants were created by introducing into NRC plasmids having DNA coding for constitutively active PKCs
- CA-PKC ⁇ CA-PKC ⁇ l, CA-PKC ⁇
- KD-PKC ⁇ kinase dead PKC ⁇
- CA-PKD1 constitutively active PKDl
- DN-PKD1 dominant negative PKDl
- GFP GFP
- cardiac hypertrophy is caused by activation of PKDl directly induced by PKC ⁇ , in the cardiomyocytes of mammals.
- cardiac hypertrophy was induced in cardiomyocytes by full activation (phosphorylation) of PKDl or activation of PKC ⁇ (Experiments 7 to 9).
- cardiac hypertrophy was not caused in cardiomyocytes into which dominant negative mutants of PKDl and PKC ⁇ have been introduced, even if treatment with the cardiac hypertrophy inducer (Angll or NE) was done (Experiments 7 to 9).
- EXPERIMENT 10 Action to suppress cardiac hypertrophy based on ENH2
- ENH1 (enigma homologue protein 1) is a protein of approximately 60kDa present specifically in heart and skeletal muscles that was isolated and identified from a rat brain-derived cDNA library by yeast two-hybrid screening using the control region of PKC ⁇ l as bait.
- ENH1 has a PDZ domain on the N-terminal side, and 3 LIM domains on the C-terminal side.
- PKDl which is phosphorylated and fully activated directly by PKC ⁇ as demonstrated by the previously described experimental results, interacts with ENHl . And the present inventors confirmed the fact that the regions of this interaction are the catalytic region positioned in the C-terminal region of PKDl and the LIM domain of ENHl. The inventors discovered that fully active PKDl and ENHl move to sarcomere Z-discs and are localized there in cardiomyocytes with cardiac hypertrophy induced by cardiac hypertrophy inducers mediated through GCPR, such as NE, Angll, etc.
- cardiac hypertrophy inducers mediated through gpl30 receptors such as LIF, etc. do not activate PKDl nor cause movement to the Z-discs.
- PKDl is activated by signaling mediated through GPCR, and moves together with ENHl to cardiomyocyte sarcomere Z-discs and becomes localized there.
- the present inventors further discovered that activated PKDl, PKC ⁇ , and ENHl interact in cardiac hypertrophy cardiomyocytes to form a complex, and localize on cardiomyocyte sarcomere Z-discs (none of this has been published) .
- Experiment NRC prepared by the same method as described in (1) of Experiment 1 was moved to a glass culture plate (35 mm diameter) coated with poly-L-lysine, and was cultured over night (5% C0 2 concentration, 37° C) in DMEM without blood serum (manufactured by Nacalai Tesque) .
- DMEM blood serum
- plasmids introduced DNA coding for FLAG fused- ENHl or FLAG fused-ENH2 were suspended with the transfection reagent (Duo Feet: Q-biogen), each of the prepared suspensions was added to NRC, thereby NRC was transformed.
- the cells were cultured in DMEM medium containing 10% FBS.
- each of the transformants FLAG fused-ENHl expressed NRC, FLAG fused-ENH2 expressed NRC was divided in two samples, and one of each was treated with 20 nM TPA, preparing TPA- treated NRC sample and untreated NRC sample.
- the TPA-treated NRC sample and untreated NRC sample of each of the transformants were double stained with anti-ANF polyclonal antibody (T4015, manufactured by Peninsula Laboratories Inc.) and anti-FLAG monoclonal antibodies (manufactured by Sigma) using the same method as in Experiment 3, and the cell luminescent signals were observed by confocal laser microscope.
- anti-ANF polyclonal antibody T4015, manufactured by Peninsula Laboratories Inc.
- anti-FLAG monoclonal antibodies manufactured by Sigma
- a deletion mutant "ENH3" derived from mouse or rat which does not have LIM domains as the ENH2, acts as an "intrinsic anti- cardiac hypertrophy antagonist" that competitvely inhibits the link of PKC to sarcomere Z-discs caused by ENHl, and suppresses and blocks the cardiac hypertrophy signal cascade.
- a conceptual diagram of a cardiac hypertrophy signal control model is indicated in Fig. 16.
- a composition for suppressing cardiac hypertrophy of the present invention which comprises as an active ingredient a substance that suppresses functional expression of PKDl in cardiomyocytes, can prevent or suppress inducement of cardiac hypertrophy by suppressing the functional expression in cardiomyocytes of PKDl, which plays a central role in the cardiac hypertrophy signal cascade.
- a composition for suppressing cardiac hypertrophy of the present invention which comprises as an active ingredient a nucleic acid (DNA) that has a base sequence coding for ENH2, can prevent or suppress inducement of cardiac hypertrophy by inhibiting the function of ENHl, which holds cardiac hypertrophy signaling factors during hypertrophy of cardiomyocytes .
- a composition for suppressing cardiac hypertrophy of the present invention can suppress the onset and development of cardiac hypertrophy by suppressing the inducement of cardiac hypertrophy, and can be effectively used as a pharmaceutical composition to prevent or remedy diseases caused by cardiac hypertrophy, specifically, heart failure, ischemic heart disease, or arrhythmia.
- PKDl is deeply related as a major component in the inducement of cardiac hypertrophy mediated through cardiac hypertrophy signaling pathway
- ENH2 is an intrinsic antagonist of ENHl related to the inducement of cardiac hypertrophy
- the non-human animal models of cardiac hypertrophy can be effectively used to conduct histological research on cardiac hypertrophy, to clarify the mechanisms of the development into cardiac hypertrophy, and to screen active ingredients for the development of cardiac hypertrophy suppressants and of preventative and remedial agents for heart disease.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002535585A CA2535585A1 (en) | 2003-08-21 | 2004-08-20 | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
EP04772292A EP1663310A1 (en) | 2003-08-21 | 2004-08-20 | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
US10/568,915 US20070135365A1 (en) | 2003-08-21 | 2004-08-20 | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby |
JP2006519271A JP4792582B2 (en) | 2003-08-21 | 2004-08-20 | Pharmaceutical composition for preventing or treating cardiac hypertrophy and heart disease resulting therefrom |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49693503P | 2003-08-21 | 2003-08-21 | |
US60/496,935 | 2003-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005018673A1 true WO2005018673A1 (en) | 2005-03-03 |
Family
ID=34216051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012336 WO2005018673A1 (en) | 2003-08-21 | 2004-08-20 | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070135365A1 (en) |
EP (1) | EP1663310A1 (en) |
JP (1) | JP4792582B2 (en) |
CA (1) | CA2535585A1 (en) |
WO (1) | WO2005018673A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7998957B2 (en) | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US8058268B2 (en) | 2008-08-01 | 2011-11-15 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8143445B2 (en) | 2007-10-01 | 2012-03-27 | Lixte Biotechnology, Inc. | HDAC inhibitors |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
JP2014001243A (en) * | 2006-08-01 | 2014-01-09 | Board Of Regents The Univ Of Texas System | Identification of microrna that activates expression of beta myosin heavy chain |
JP2014221042A (en) * | 2006-08-21 | 2014-11-27 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | Neukinase which is downstream protein of neuregulin |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US11253573B2 (en) | 2011-10-10 | 2022-02-22 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure |
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
EP2871461A1 (en) * | 2013-11-06 | 2015-05-13 | F. Hoffmann-La Roche AG | Method for examining a plurality of cultured cells for the presence of periodic structures of at least one target component contained in the cultured cells |
CN108913655B (en) * | 2018-07-16 | 2022-07-15 | 浙江大学 | Method for establishing human-derived myocardial hypertrophy model based on pluripotent stem cell technology |
CN109321602B (en) * | 2018-10-16 | 2021-11-30 | 汉恒生物科技(上海)有限公司 | PKD2 recombinant overexpression vector and construction method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003055266A (en) * | 2001-06-04 | 2003-02-26 | Univ Texas Syst | Method and composition relating to mek5, cardiomegaly, and dilated cardiomyopathy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007505158A (en) * | 2003-05-21 | 2007-03-08 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | Inhibition of protein kinase C-μ (PKD) as a treatment for cardiac hypertrophy and heart failure |
-
2004
- 2004-08-20 CA CA002535585A patent/CA2535585A1/en not_active Abandoned
- 2004-08-20 JP JP2006519271A patent/JP4792582B2/en active Active
- 2004-08-20 US US10/568,915 patent/US20070135365A1/en not_active Abandoned
- 2004-08-20 EP EP04772292A patent/EP1663310A1/en not_active Withdrawn
- 2004-08-20 WO PCT/JP2004/012336 patent/WO2005018673A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003055266A (en) * | 2001-06-04 | 2003-02-26 | Univ Texas Syst | Method and composition relating to mek5, cardiomegaly, and dilated cardiomyopathy |
Non-Patent Citations (6)
Title |
---|
FREY N. ET AL.: "Cardiac hypertrophy: the good, the bad, and the ugly", ANNU. REV. PHYSIOL., vol. 65, 2003, pages 45 - 79, XP002982981 * |
IWATA M. ET AL.: "Biological significance of the ENH1-PCKepsilon-PKD1 complex in cardiac hypertrophy", SEIKAGAKU, vol. 75, no. 8, 25 August 2003 (2003-08-25), pages 992, XP002982982 * |
MOCHLY-ROSEN D. ET AL.: "Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon", TRANSLOCATION. CIRC. RES., vol. 86, 2000, pages 1173 - 1179, XP002982980 * |
NAKAGAWA N. ET AL.: "ENH. containing PDZ and LIM domains, heart/skeltal muscle-specific protein, associates with cytoskeltal proteins through the PDZ domain", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 272, 2000, pages 505 - 512, XP002982979 * |
VAN LINT J. ET AL.: "Protein kinase D: an intracellular traffic regulator on the move", TRENDS BIOL., vol. 12, no. 4, 2002, pages 193 - 200, XP002982978 * |
VEGA R.B. ET AL.: "Protein kinase C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase", MOL. CELL. BIOL., vol. 24, no. 19, October 2004 (2004-10-01), pages 8374 - 8385, XP002982983 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014001243A (en) * | 2006-08-01 | 2014-01-09 | Board Of Regents The Univ Of Texas System | Identification of microrna that activates expression of beta myosin heavy chain |
US10227418B2 (en) | 2006-08-21 | 2019-03-12 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
JP2014221042A (en) * | 2006-08-21 | 2014-11-27 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | Neukinase which is downstream protein of neuregulin |
US9079917B2 (en) | 2007-02-06 | 2015-07-14 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US7998957B2 (en) | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
US10023587B2 (en) | 2007-02-06 | 2018-07-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US10399993B2 (en) | 2007-02-06 | 2019-09-03 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US8455688B2 (en) | 2007-10-01 | 2013-06-04 | Lixte Biotechnology, Inc. | HDAC inhibitors |
US8143445B2 (en) | 2007-10-01 | 2012-03-27 | Lixte Biotechnology, Inc. | HDAC inhibitors |
US8329719B2 (en) | 2008-08-01 | 2012-12-11 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9526915B2 (en) | 2008-08-01 | 2016-12-27 | John S. Kovach | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US8058268B2 (en) | 2008-08-01 | 2011-11-15 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
US11253573B2 (en) | 2011-10-10 | 2022-02-22 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure |
US11931354B2 (en) | 2013-04-09 | 2024-03-19 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
Also Published As
Publication number | Publication date |
---|---|
JP4792582B2 (en) | 2011-10-12 |
EP1663310A1 (en) | 2006-06-07 |
US20070135365A1 (en) | 2007-06-14 |
JP2007528861A (en) | 2007-10-18 |
CA2535585A1 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kovacic-Milivojevic et al. | Focal adhesion kinase and p130Cas mediate both sarcomeric organization and activation of genes associated with cardiac myocyte hypertrophy | |
Rottbauer et al. | VEGF–PLCγ1 pathway controls cardiac contractility in the embryonic heart | |
De Acetis et al. | Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload | |
Hirsch et al. | Defective Rac-mediated proliferation and survival after targeted mutation of the β1 integrin cytodomain | |
Lal et al. | Stretch-induced MAP kinase activation in cardiac myocytes: differential regulation through β1-integrin and focal adhesion kinase | |
KR20090089462A (en) | Compositions and methods for treating pathologic angiogenesis and vascular permeability | |
US20070135365A1 (en) | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby | |
KR100553300B1 (en) | Promotion or Inhibition of Angiogenesis and Cardiovascularization | |
US20080085323A1 (en) | Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders | |
US20110288149A1 (en) | Method of protecting against heart failure | |
CN107847523A (en) | Fissional method for cell after induced mitogenesis | |
US20090136482A1 (en) | Drug target protein and target gene, and screening method | |
Tsoporis et al. | S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes | |
WO2006039630A2 (en) | Materials and methods for identifying compounds that modulate the cell cycle | |
JP5229721B2 (en) | Screening method for Nesfatin-1 action-regulating substance or Nesfatin-1-like substance using receptor protein selected from the group consisting of GPR3, GPR6, and GPR12 | |
Dasgupta et al. | Misregulation of connexin43 gap junction channels and congenital heart defects | |
US8153385B2 (en) | Target protein and target gene in drug designing and screening method | |
Dailey-Krempel et al. | A tug of war between DCC and ROBO1 signaling during commissural axon guidance | |
Fu | Molecular mechanisms underlying GRK2 inhibition by RKIP in vitro and in vivo | |
WO2003025579A2 (en) | Use of heart fatty acid binding protein | |
Dube et al. | Understanding the Relevance of Tpm1k Expression–Past, Present and Future | |
Main | Characterising the palmitoylation and SUMOylation of cardiac myosin binding protein-C in cardiac health and disease | |
Abou Al Saud | Investigation of phenotypic rescue of Mybpc3 deficient mouse | |
Ehsan | Characterization of cardiomyopathy causing mutation in muscle lim protein (C58G) | |
Jang | Functional Characterization of Scaffold Protein Shoc2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2535585 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006519271 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004772292 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004772292 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007135365 Country of ref document: US Ref document number: 10568915 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10568915 Country of ref document: US |